All	O
live	O
births	O
>	O
or	O
=	O
23	O
weeks	O
at	O
the	O
University	O
of	O
Vermont	O
in	O
1995	O
(	O
n	O
=	O
2395	O
)	O
were	O
retrospectively	O
analyzed	O
for	O
delivery	O
route	O
,	O
indication	O
for	O
cesarean	O
,	O
gestational	O
age	O
,	O
parity	O
,	O
and	O
practice	O
group	O
(	O
to	O
reflect	O
risk	O
status	O
)	O

The	O
total	O
cesarean	O
rate	O
was	O
14.4	O
%	O
(	O
344	O
of	O
2395	O
)	O
,	O
and	O
the	O
primary	O
rate	O
was	O
11.4	O
%	O
(	O
244	O
of	O
2144	O
)	O

Abnormal	O
presentation	O
was	O
the	O
most	O
common	O
indication	O
(	O
25.6	O
%	O
,	O
88	O
of	O
344	O
)	O

The	O
``	O
corrected	O
''	O
cesarean	O
rate	O
(	O
maternal-fetal	O
medicine	O
and	O
transported	O
patients	O
excluded	O
)	O
was	O
12.4	O
%	O
(	O
273	O
of	O
2194	O
)	O
,	O
and	O
the	O
``	O
corrected	O
''	O
primary	O
rate	O
was	O
9.6	O
%	O
(	O
190	O
of	O
1975	O
)	O

Furthermore	O
,	O
when	O
all	O
deliveries	O
were	O
analyzed	O
,	O
regardless	O
of	O
risk	O
status	O
but	O
limited	O
to	O
gestational	O
age	O
>	O
or	O
=	O
36	O
weeks	O
,	O
the	O
rates	O
did	O
not	O
change	O
(	O
12.6	O
%	O
,	O
280	O
of	O
2214	O
;	O
primary	O
9.2	O
%	O
,	O
183	O
of	O
1994	O
)	O

Arrest	O
of	O
dilation	O
was	O
the	O
most	O
common	O
indication	O
in	O
both	O
``	O
corrected	O
''	O
subgroups	O
(	O
23.4	O
and	O
24.6	O
%	O
,	O
respectively	O
)	O

Cesarean	O
rates	O
at	O
tertiary	O
care	O
hospitals	O
should	O
be	O
compared	O
with	O
rates	O
at	O
community	O
hospitals	O
only	O
after	O
correcting	O
for	O
dissimilar	O
patient	O
groups	O
or	O
gestational	O
age	O

In	O
the	O
third	O
trimester	O
,	O
the	O
amniotic	O
fluid	O
index	O
(	O
AFI	O
)	O
may	O
be	O
affected	O
by	O
maternal	O
fluid	O
status	O

As	O
the	O
ambient	O
temperature	O
increases	O
,	O
there	O
is	O
an	O
increase	O
in	O
insensible	O
fluid	O
loss	O
and	O
the	O
potential	O
for	O
dehydration	O

We	O
hypothesize	O
that	O
as	O
temperature	O
increases	O
there	O
would	O
be	O
a	O
concomitant	O
decrease	O
in	O
AFI	O

From	O
June	O
11	O
to	O
August	O
16	O
,	O
1993	O
,	O
during	O
a	O
period	O
of	O
unusual	O
high	O
heat	O
,	O
42	O
women	O
with	O
singleton	O
pregnancies	O
between	O
27	O
and	O
40	O
weeks	O
'	O
gestation	O
undergoing	O
serial	O
antenatal	O
testing	O
had	O
AFI	O
determinations	O
recorded	O
at	O
least	O
weekly	O

The	O
daily	O
high	O
ambient	O
temperature	O
in	O
our	O
urban	O
area	O
was	O
subsequently	O
obtained	O

A	O
2-	O
,	O
3-	O
,	O
and	O
4-day	O
mean	O
temperature	O
prior	O
to	O
the	O
test	O
date	O
was	O
compared	O
to	O
AFI	O
using	O
a	O
Spearman-rank	O
Correlation	O

The	O
daily	O
high	O
temperature	O
ranged	O
from	O
71	O
to	O
104	O
degrees	O
F	O
and	O
AFI	O
values	O
ranged	O
from	O
1.7	O
to	O
24.7	O
cm	O
during	O
the	O
study	O
period	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
2-	O
,	O
3-	O
,	O
and	O
4-day	O
mean	O
temperature	O
and	O
AFI	O
,	O
with	O
the	O
4-day	O
mean	O
being	O
the	O
most	O
significant	O
(	O
r	O
=	O
0.31	O
,	O
p	O
&	O
#	O
60	O
;	O
0.001	O
)	O

Fluctuations	O
in	O
ambient	O
temperature	O
are	O
inversely	O
correlated	O
to	O
changes	O
in	O
AFI	O

This	O
relationship	O
should	O
be	O
taken	O
into	O
account	O
when	O
interpreting	O
the	O
AFI	O
as	O
a	O
measure	O
of	O
fetal	O
well-being	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
to	O
reduce	O
the	O
rate	O
of	O
macrosomic	O
infants	O
in	O
gestational	O
diabetes	O
cases	O
,	O
good	O
glycemic	O
control	O
should	O
be	O
initiated	O
before	O
34	O
completed	O
gestational	O
weeks	O

The	O
study	O
population	O
included	O
84	O
women	O
with	O
gestational	D
diabetes	D
,	O
ascertained	O
by	O
universal	O
screening	O
of	O
all	O
women	O
attending	O
the	O
antenatal	O
clinic	O
of	O
the	O
Hadassah	O
Medical	O
Center	O
,	O
over	O
a	O
2-year	O
period	O

The	O
60	O
women	O
(	O
71	O
%	O
)	O
,	O
who	O
initiated	O
treatment	O
before	O
34	O
completed	O
weeks	O
,	O
composed	O
the	O
``	O
early	O
''	O
group	O

The	O
24	O
women	O
(	O
29	O
%	O
)	O
,	O
who	O
initiated	O
treatment	O
after	O
the	O
34th	O
week	O
,	O
composed	O
the	O
``	O
late	O
''	O
group	O

All	O
patients	O
were	O
managed	O
by	O
an	O
intensified	O
protocol	O
,	O
including	O
stringent	O
glycemic	T
control	T

In	O
the	O
``	O
early	O
''	O
and	O
``	O
late	O
''	O
groups	O
,	O
mean	O
gestational	O
age	O
at	O
the	O
beginning	O
of	O
treatment	O
was	O
30.0	O
+/-	O
3.8	O
and	O
36.2	O
+/-	O
1.2	O
weeks	O
,	O
and	O
duration	O
of	O
treatment	O
was	O
9.6	O
+/-	O
4.1	O
and	O
3.7	O
+/-	O
1.8	O
weeks	O
,	O
respectively	O

Maternal	O
characteristics	O
were	O
similar	O
in	O
the	O
two	O
groups	O

The	O
rate	O
of	O
macrosomic	O
and	O
large-for-gestational-age	O
infants	O
were	O
5	O
and	O
11	O
%	O
,	O
respectively	O
,	O
in	O
the	O
early	O
group	O
as	O
compared	O
to	O
25	O
and	O
29	O
%	O
in	O
the	O
``	O
late	O
''	O
group	O
(	O
p	O
&	O
#	O
60	O
;	O
0.05	O
)	O

No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
two	O
groups	O
in	O
the	O
mode	O
of	O
delivery	O
or	O
Apgar	O
scores	O

We	O
conclude	O
that	O
to	O
reduce	O
the	O
rate	O
of	O
macrosomic	D
infants	D
in	D
gestational	D
diabetes	D
cases	D
,	O
good	T
glycemic	T
control	T
should	O
be	O
initiated	O
before	O
34	O
completed	O
gestational	O
weeks	O

Our	O
aim	O
was	O
to	O
investigate	O
the	O
contribution	O
of	O
certain	O
antenatally	O
detectable	O
markers	O
leading	O
to	O
the	O
diagnosis	O
of	O
trisomic	O
fetuses	O
we	O
observed	O
over	O
a	O
period	O
of	O
6	O
years	O

In	O
our	O
study	O
,	O
we	O
specifically	O
analyzed	O
the	O
role	O
played	O
by	O
advanced	O
maternal	O
age	O
and	O
sonographically	O
discovered	O
abnormalities	O
in	O
the	O
detection	O
of	O
autosomal	D
trisomies	D

All	O
together	O
,	O
27	O
fetuses	O
had	O
this	O
disorder	O
,	O
representing	O
28.7	O
%	O
(	O
27	O
of	O
94	O
)	O
of	O
all	O
cytogenetic	D
aberrations	D
detected	O
at	O
our	O
center	O
over	O
the	O
same	O
period	O

Down	D
syndrome	D
(	O
12	O
cases	O
)	O
and	O
Edward	D
syndrome	D
(	O
11	O
cases	O
)	O
were	O
the	O
most	O
common	O
trisomies	D
,	O
while	O
4	O
cases	O
of	O
Patau	D
syndrome	D
were	O
also	O
diagnosed	O

The	O
most	O
common	O
indication	O
leading	O
to	O
diagnosis	O
was	O
abnormal	O
ultrasound	O
finding	O
(	O
48.2	O
%	O
)	O
,	O
followed	O
by	O
advanced	O
maternal	O
age	O
(	O
44.4	O
%	O
)	O

However	O
,	O
63	O
%	O
of	O
the	O
trisomic	O
fetuses	O
belonged	O
to	O
mothers	O
aged	O
35	O
years	O
and	O
above	O

Down	D
syndrome	D
fetuses	O
(	O
41.7	O
%	O
)	O
had	O
prenatally	O
detected	O
sonographic	O
anomalies	O
,	O
63.6	O
%	O
for	O
Edward	D
syndrome	D
,	O
and	O
all	O
fetuses	O
with	O
Patau	D
syndrome	D
(	O
4	O
of	O
4	O
)	O
showed	O
abnormal	O
sonographic	O
signs	O

Trisomy	D
21	D
presented	O
with	O
the	O
following	O
features	O
:	O
hydramnios	O
,	O
complex	O
malformations	O
,	O
pyelectasis	D
,	O
and	O
duodenal	D
atresia	D

Trisomy	D
18	D
fetuses	O
showed	O
hydramnios	O
,	O
intrauterine	O
growth	O
retardation	O
,	O
microcephaly	D
,	O
spina	D
bifida	D
,	O
and	O
nonimmune	D
hydrops	D
fetalis	D

Signs	O
observed	O
in	O
fetuses	O
with	O
trisomy	D
13	D
were	O
:	O
hydrocephalus	O
,	O
intrauterine	O
growth	O
retardation	O
,	O
oligoanhydramnios	O
,	O
complex	O
malformations	O
,	O
severe	O
fetal	O
bradycardia	D
and	O
hydronephrosis	D

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
the	O
rate	O
of	O
preeclampsia	D
is	O
increased	O
in	O
triplet	O
as	O
compared	O
to	O
twin	O
gestations	O

Fifty-three	O
triplet	O
pregnancies	O
between	O
1986	O
and	O
1993	O
at	O
The	O
New	O
York	O
Hospital-Cornell	O
Medical	O
Center	O
were	O
reviewed	O

These	O
were	O
matched	O
for	O
maternal	O
age	O
,	O
parity	O
,	O
and	O
race	O
to	O
twin	O
gestations	O
(	O
N	O
=	O
53	O
)	O
from	O
the	O
same	O
population	O

Severe	O
preeclampsia	D
was	O
defined	O
by	O
standard	O
criteria	O

Student	O
's	O
t-test	O
,	O
Fisher	O
exact	O
test	O
,	O
and	O
Chi-square	O
were	O
used	O
for	O
statistical	O
analysis	O

The	O
rate	O
of	O
severe	O
preeclampsia	D
was	O
increased	O
significantly	O
in	O
the	O
triplet	O
group	O
12	O
of	O
53	O
(	O
22.6	O
%	O
)	O
as	O
compared	O
with	O
the	O
twin	O
group	O
3	O
of	O
53	O
(	O
5.7	O
%	O
)	O
(	O
OR	O
=	O
4.9	O
,	O
95	O
%	O
CI	O
1.2-23.5	O
,	O
p	O
=	O
0.02	O
)	O

The	O
rate	O
of	O
overall	O
preeclampsia	D
was	O
not	O
significantly	O
different	O
in	O
the	O
triplet	O
18	O
of	O
53	O
(	O
33.96	O
%	O
)	O
or	O
twin	O
12	O
of	O
53	O
(	O
22.6	O
%	O
)	O
groups	O

In	O
this	O
retrospective	O
,	O
case-controlled	O
study	O
,	O
the	O
rate	O
of	O
severe	O
pre-eclampsia	D
was	O
significantly	O
increased	O
in	O
triplet	O
gestations	O
as	O
compared	O
to	O
twins	O
although	O
the	O
overall	O
rate	O
of	O
preeclampsia	D
was	O
not	O

This	O
information	O
may	O
be	O
useful	O
in	O
counseling	O
patients	O
with	O
high	O
order	O
multifetal	O
gestations	O

We	O
conducted	O
a	O
survey	O
and	O
audit	O
of	O
thermal	O
equipment	O
use	O
in	O
very	O
low-birth-weight	O
infants	O
in	O
five	O
Ohio	O
neonatal	O
intensive	O
care	O
units	O
(	O
NICUs	O
)	O
to	O
document	O
regional	O
practice	O

The	O
survey	O
indicated	O
a	O
variety	O
of	O
thermal	O
care	O
styles	O

Two	O
NICUs	O
preferred	O
to	O
admit	O
infants	O
to	O
incubators	O
,	O
the	O
other	O
three	O
favoring	O
radiant	O
warmers	O

These	O
three	O
NICUs	O
moved	O
infants	O
from	O
radiant	O
warmers	O
into	O
incubators	O
at	O
significantly	O
different	O
mean	O
ages	O

The	O
audit	O
demonstrated	O
inconsistent	O
use	O
of	O
plastic	O
covers	O
,	O
warming	O
mattresses	O
,	O
and	O
added	O
humidity	O
under	O
radiant	O
warmers	O
,	O
and	O
discrepancies	O
between	O
survey	O
responses	O
and	O
actual	O
use	O
within	O
NICUs	O

Inter-NICU	O
variability	O
of	O
thermal	O
equipment	O
use	O
may	O
complicate	O
fluid	O
management	O

This	O
report	O
describes	O
a	O
full-term	O
newborn	O
with	O
massive	D
fetomaternal	D
hemorrhage	D

Fetal	O
movements	O
were	O
decreased	O
48	O
hr	O
prior	O
to	O
delivery	O

On	O
the	O
day	O
of	O
delivery	O
,	O
they	O
were	O
absent	O

The	O
nonstress	O
test	O
was	O
abnormal	O
with	O
low	O
biophysical	O
profile	O
and	O
decreased	O
beat-to-beat	O
variability	O

The	O
infant	O
presented	O
with	O
extreme	O
pallor	O
,	O
hypotonia	D
,	O
hepatosplenomegaly	D
,	O
and	O
ascites	D

The	O
initial	O
hemoglobin	O
was	O
2.2	O
g/dL	O
,	O
the	O
Kleihauer-Betke	O
stain	O
was	O
27.6	O
%	O
(	O
highest	O
level	O
ever	O
reported	O
)	O

Right	O
temporal	O
and	O
cerebellar	O
hemorrhages	O
were	O
present	O

Sequelae	O
include	O
severe	O
developmental	O
delay	O
and	O
asymmetric	O
double	O
hemiplegia	D

Omphalocele-Exstrophy-Imperforate	D
anus-Spinal	D
defects	D
(	D
OEIS	D
complex	D
)	D
,	O
a	O
combination	O
of	O
omphalocele	D
,	O
exstrophy	D
of	D
the	D
bladder	D
,	O
an	O
imperforate	O
anus	O
and	O
spinal	D
defects	D
,	O
arises	O
from	O
a	O
single	O
localized	O
defect	O
in	O
the	O
early	O
development	O
of	O
the	O
mesoderm	O
that	O
will	O
later	O
contribute	O
to	O
infraumbilical	O
mesenchyme	O
,	O
cloacal	O
septum	O
,	O
and	O
caudal	O
vertebrae	O

In	O
this	O
report	O
,	O
we	O
document	O
the	O
perinatal	O
features	O
of	O
two	O
cases	O
of	O
OEIS	D
complex	D
associated	O
with	O
meningomyeloceles	D
and	O
severe	O
lower	O
limb	O
defects	O
,	O
and	O
discuss	O
the	O
prenatal	O
diagnosis	O
,	O
inheritance	O
,	O
and	O
differential	O
diagnosis	O
of	O
this	O
association	O
of	O
malformations	O

Although	O
long-term	O
survival	O
can	O
be	O
achieved	O
by	O
successful	O
corrective	T
surgery	T
,	O
the	O
associated	O
structural	O
defects	O
such	O
as	O
large	D
meningomyelocele	D
and	O
severe	O
limb	D
aplasia	D
or	O
hypoplasia	D
,	O
as	O
seen	O
in	O
our	O
patient	O
,	O
can	O
influence	O
the	O
patient	O
's	O
quality	O
of	O
life	O
.	O

We	O
would	O
like	O
to	O
emphasize	O
that	O
an	O
accurate	O
prenatal	O
diagnosis	O
of	O
OEIS	D
complex	D
and	O
associated	O
malformations	O
is	O
important	O
for	O
the	O
detailed	O
counseling	O
of	O
the	O
family	O
as	O
well	O
as	O
appropriate	O
perinatal	O
management	O
by	O
the	O
obstetricians	O
,	O
pediatric	O
surgeons	O
,	O
urologists	O
,	O
neurosurgeons	O
,	O
and	O
neonatologists	O

Nonimmune	D
hydrops	D
fetails	D
diagnosed	O
at	O
21	O
weeks	O
'	O
gestation	O
with	O
profound	O
ascites	D
,	O
hydrothorax	D
,	O
and	O
pericardial	D
effusion	D
receded	O
gradually	O
with	O
regression	O
of	O
a	O
subchorial	O
placental	O
lucencies	O
immediately	O
below	O
the	O
umbilical	O
cord	O
insertion	O

Careful	O
inspection	O
of	O
the	O
delivered	O
placenta	O
revealed	O
that	O
there	O
was	O
a	O
yellowish	O
lesion	O
of	O
fibrin	O
deposits	O
below	O
the	O
cord	O
insertion	O
site	O
,	O
which	O
resulted	O
from	O
the	O
absorption	O
of	O
hematoma	O

A	O
subchorial	O
placental	O
hematoma	D
,	O
which	O
detected	O
as	O
a	O
subchorial	O
placental	O
lucencies	D
by	O
ultrasonography	O
,	O
can	O
be	O
a	O
cause	O
of	O
reversible	O
nonimmune	D
hydrops	D
fetalis	D

The	O
mitochondrial	D
diseases	D
are	O
uncommon	O
multisystem	O
disorders	O
characterized	O
by	O
the	O
presence	O
of	O
functionally	O
and/or	O
structurally	O
abnormal	O
mitochondria	O

As	O
there	O
have	O
been	O
few	O
reports	O
of	O
the	O
obstetrical	O
care	O
of	O
affected	O
patients	O
,	O
we	O
wish	O
to	O
document	O
two	O
pregnancies	O
in	O
a	O
woman	O
with	O
a	O
Chronic	D
Progressive	D
External	D
Ophthalmoplegia	D
(	D
Kearns-Sayre-like	D
syndrome	D
)	D

Both	O
pregnancies	O
were	O
complicated	O
by	O
preterm	O
labor	O
and	O
hypertension	D

CONTEXT	O
:	O
Four	O
genetic	O
loci	O
have	O
been	O
identified	O
as	O
contributing	O
to	O
Alzheimer	D
disease	D
(	D
AD	D
)	D
,	O
including	O
the	O
amyloid	O
precursor	O
protein	O
gene	O
,	O
the	O
presenilin	O
1	O
gene	O
,	O
the	O
presenilin	O
2	O
gene	O
,	O
and	O
the	O
apolipoprotein	O
E	O
gene	O
,	O
but	O
do	O
not	O
account	O
for	O
all	O
the	O
genetic	O
risk	O
for	O
AD	O

OBJECTIVE	O
:	O
To	O
identify	O
additional	O
genetic	O
risk	O
factors	O
for	O
late-onset	O
AD	O

DESIGN	O
:	O
A	O
complete	O
genomic	O
screen	O
was	O
performed	O
(	O
N=280	O
markers	O
)	O

Critical	O
values	O
for	O
chromosomal	O
regional	O
follow-up	O
were	O
a	O
P	O
value	O
of	O
.05	O
or	O
less	O
for	O
affected	O
relative	O
pair	O
analysis	O
or	O
sibpair	O
analysis	O
,	O
a	O
parametric	O
lod	O
score	O
of	O
1.0	O
or	O
greater	O
,	O
or	O
both	O

Regional	O
follow-up	O
included	O
analysis	O
of	O
additional	O
markers	O
and	O
a	O
second	O
data	O
set	O

SETTING	O
:	O
Clinic	O
populations	O
in	O
the	O
continental	O
United	O
States	O

PATIENTS	O
:	O
>	O
From	O
a	O
series	O
of	O
multiplex	O
families	O
affected	O
with	O
late-onset	O
(	O
>	O
or	O
=60	O
years	O
)	O
AD	O
ascertained	O
during	O
the	O
last	O
14	O
years	O
(	O
National	O
Insititute	O
of	O
Neurological	O
Disorders	O
and	O
Stroke-Alzheimer	O
's	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
diagnostic	O
criteria	O
)	O
and	O
for	O
which	O
DNA	O
has	O
been	O
obtained	O
,	O
a	O
subset	O
of	O
16	O
families	O
(	O
135	O
total	O
family	O
members	O
,	O
52	O
of	O
whom	O
were	O
patients	O
with	O
AD	O
)	O
was	O
used	O
for	O
the	O
genomic	O
screen	O

A	O
second	O
subset	O
of	O
38	O
families	O
(	O
216	O
total	O
family	O
members	O
,	O
89	O
of	O
whom	O
were	O
patients	O
with	O
AD	O
)	O
was	O
used	O
for	O
the	O
follow-up	O
analysis	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Linkage	O
analysis	O
results	O
generated	O
using	O
both	O
genetic	O
model-dependent	O
(	O
lod	O
score	O
)	O
and	O
model-independent	O
methods	O

RESULTS	O
:	O
Fifteen	O
chromosomal	O
regions	O
warranted	O
initial	O
follow-up	O

Follow-up	O
analyses	O
revealed	O
4	O
regions	O
of	O
continued	O
interest	O
on	O
chromosomes	O
4	O
,	O
6	O
,	O
12	O
,	O
and	O
20	O
,	O
with	O
the	O
strongest	O
results	O
observed	O
forchromosome	O
12	O

Peak	O
2-point	O
affecteds-only	O
lod	O
scores	O
(	O
n=54	O
)	O
were	O
1.3	O
,	O
1.6	O
,	O
2.7	O
,	O
and	O
2.2	O
and	O
affected	O
relative	O
pairs	O
P	O
values	O
(	O
n=54	O
)	O
were	O
.04	O
,	O
.03	O
,	O
.14	O
,	O
and	O
.04	O
for	O
D12S373	O
,	O
D12S1057	O
,	O
D12S1042	O
,	O
and	O
D12S390	O
,	O
respectively	O

Sibpair	O
analysis	O
(	O
n=54	O
)	O
resulted	O
in	O
maximum	O
lod	O
scores	O
(	O
MLSs	O
)	O
of	O
1.5	O
,	O
2.6	O
,	O
3.2	O
,	O
and	O
2.3	O
for	O
these	O
markers	O
,	O
with	O
a	O
peak	O
multipoint	O
MLS	O
of	O
3.5	O

A	O
priori	O
stratification	O
by	O
APOE	O
genotype	O
identified	O
27	O
families	O
that	O
had	O
at	O
least	O
1	O
member	O
with	O
AD	O
whose	O
genotype	O
did	O
not	O
contain	O
an	O
APOE*4	O
allele	O

Analysis	O
of	O
these	O
27	O
families	O
resulted	O
in	O
MLSs	O
of	O
1.0	O
,	O
2.4	O
,	O
3.7	O
,	O
and	O
3.3	O
and	O
a	O
peak	O
multipoint	O
MLS	O
of	O
3.9	O

CONCLUSIONS	O
:	O
A	O
complete	O
genomic	O
screen	O
in	O
families	O
affected	O
with	O
late-onset	O
AD	O
identified	O
4	O
regions	O
of	O
interest	O
after	O
follow-up	O

Chromosome	O
12	O
gave	O
the	O
strongest	O
and	O
most	O
consistent	O
results	O
with	O
a	O
peak	O
multipoint	O
MLS	O
of	O
3.5	O
,	O
suggesting	O
that	O
this	O
region	O
contains	O
a	O
new	O
susceptibility	O
gene	O
for	O
AD	O

Additional	O
analyses	O
are	O
necessary	O
to	O
identify	O
the	O
chromosome	O
12	O
susceptibility	O
gene	O
for	O
AD	O
and	O
to	O
follow	O
up	O
the	O
regions	O
of	O
interest	O
on	O
chromosomes	O
4	O
,	O
6	O
,	O
and	O
20	O

CONTEXT	O
:	O
A	O
mutation	O
in	O
the	O
BRCA1	O
gene	O
may	O
confer	O
substantial	O
risk	O
for	O
breast	O
and/or	O
ovarian	O
cancer	D

However	O
,	O
knowledge	O
regarding	O
all	O
possible	O
mutations	O
and	O
the	O
relationship	O
between	O
risk	O
factors	O
and	O
mutations	O
is	O
incomplete	O

OBJECTIVES	O
:	O
To	O
identify	O
BRCA1	O
mutations	O
and	O
to	O
determine	O
factors	O
that	O
best	O
predict	O
presence	O
of	O
a	O
deleterious	O
BRCA1	O
mutation	O
in	O
patients	O
with	O
breast	O
and/or	O
ovarian	O
cancer	D

DESIGN	O
:	O
A	O
complete	O
sequence	O
analysis	O
of	O
the	O
BRCA1	O
coding	O
sequence	O
and	O
flanking	O
intronic	O
regions	O
was	O
performed	O
in	O
798	O
women	O
in	O
a	O
collaborative	O
effort	O
involving	O
institutions	O
from	O
the	O
United	O
States	O
,	O
Italy	O
,	O
Germany	O
,	O
Finland	O
,	O
and	O
Switzerland	O

PARTICIPANTS	O
:	O
Institutions	O
selected	O
798	O
persons	O
representing	O
families	O
(	O
1	O
person	O
for	O
each	O
family	O
)	O
thought	O
to	O
be	O
at	O
elevated	O
a	O
priori	O
risk	O
of	O
BRCA1	O
mutation	O
due	O
to	O
potential	O
risk	O
factors	O
,	O
such	O
as	O
multiple	O
cases	O
of	O
breast	D
cancer	D
,	O
early	O
age	O
of	O
breast	D
cancer	D
diagnosis	O
,	O
and	O
cases	O
of	O
ovarian	D
cancer	D

No	O
participant	O
was	O
from	O
a	O
family	O
in	O
which	O
genetic	O
markers	O
showed	O
linkage	O
to	O
the	O
BRCA1	O
locus	O

MAJOR	O
OUTCOME	O
MEASURES	O
:	O
Sequence	O
variants	O
detected	O
in	O
this	O
sample	O
are	O
presented	O
along	O
with	O
analyses	O
designed	O
to	O
determine	O
predictive	O
characteristics	O
of	O
those	O
testing	O
positive	O
for	O
BRCA1	O
mutations	O

RESULTS	O
:	O
In	O
102	O
women	O
(	O
12.8	O
%	O
)	O
,	O
clearly	O
deleterious	O
mutations	O
were	O
detected	O

Fifty	O
new	O
genetic	O
alterations	O
were	O
found	O
including	O
24	O
deleterious	O
mutations	O
,	O
24	O
variants	O
of	O
unknown	O
significance	O
,	O
and	O
2	O
rare	O
polymorphisms	O

In	O
a	O
subset	O
of	O
71	O
Ashkenazi	O
Jewish	O
women	O
,	O
only	O
2	O
distinct	O
deleterious	O
mutations	O
were	O
found	O
:	O
185delAG	O
in	O
17	O
cases	O
and	O
5382insC	O
in	O
7	O
cases	O

A	O
bias	O
in	O
prior	O
reports	O
for	O
mutations	O
in	O
exon	O
11	O
was	O
revealed	O

Characteristics	O
of	O
a	O
patient	O
's	O
specific	O
diagnosis	O
(	O
unilateral	O
or	O
bilateral	O
breast	D
cancer	D
,	O
with	O
or	O
without	O
ovarian	D
cancer	D
)	O
,	O
early	O
age	O
at	O
diagnosis	O
,	O
Ashkenazi	O
Jewish	O
ethnicity	O
,	O
and	O
family	O
history	O
of	O
cancer	O
were	O
positively	O
associated	O
with	O
the	O
probability	O
of	O
her	O
carrying	O
a	O
deleterious	O
BRCA1	O
mutation	O

CONCLUSIONS	O
:	O
Using	O
logistic	O
regression	O
analysis	O
,	O
we	O
provide	O
a	O
method	O
for	O
evaluating	O
the	O
probability	O
of	O
a	O
woman	O
's	O
carrying	O
a	O
deleterious	O
BRCA1	O
mutation	O
for	O
a	O
wide	O
range	O
of	O
cases	O
,	O
which	O
can	O
be	O
an	O
important	O
tool	O
for	O
clinicians	O
as	O
they	O
incorporate	O
genetic	O
susceptibility	O
testing	O
into	O
their	O
medical	O
practice	O

CONTEXT	O
:	O
Approximately	O
9	O
%	O
of	O
prostate	D
cancer	D
cases	O
have	O
been	O
estimated	O
to	O
result	O
from	O
inheritance	O
of	O
mutated	O
prostate	O
cancer	O
susceptibility	O
genes	O

Few	O
data	O
exist	O
as	O
to	O
whether	O
there	O
are	O
clinical	O
differences	O
between	O
prostate	D
cancers	D
that	O
are	O
inherited	O
and	O
those	O
that	O
occur	O
in	O
the	O
general	O
population	O

OBJECTIVE	O
:	O
To	O
investigate	O
phenotypic	O
characteristics	O
of	O
families	O
potentially	O
linked	O
to	O
the	O
hereditary	O
prostate	O
cancer	O
1	O
(	O
HPC1	O
)	O
locus	O
on	O
chromosome	O
1q24-25	O

DESIGN	O
:	O
Retrospective	O
case	O
study	O
in	O
which	O
clinical	O
data	O
were	O
extracted	O
from	O
medical	O
and	O
pathological	O
records	O

FAMILIES	O
:	O
A	O
total	O
of	O
74	O
North	O
American	O
families	O
with	O
hereditary	O
prostate	D
cancer	D

Prostate	O
cancer	O
cases	O
from	O
the	O
National	O
Cancer	O
Data	O
Base	O
were	O
used	O
as	O
a	O
reference	O
population	O
for	O
comparison	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
The	O
families	O
were	O
divided	O
into	O
2	O
groups	O
:	O
either	O
potentially	O
linked	O
(	O
33	O
families	O
with	O
133	O
men	O
with	O
prostate	D
cancer	D
)	O
,	O
and	O
thus	O
likely	O
to	O
be	O
carrying	O
an	O
altered	O
HPC1	O
gene	O
,	O
or	O
potentially	O
unlinked	O
(	O
41	O
families	O
with	O
172	O
men	O
with	O
prostate	D
cancer	D
)	O
,	O
on	O
the	O
basis	O
of	O
haplotype	O
analysis	O
in	O
the	O
region	O
of	O
HPC1	O

The	O
age	O
at	O
diagnosis	O
of	O
prostate	D
cancer	D
,	O
serum	O
prostate-specific	O
antigen	O
levels	O
,	O
digital	O
rectal	O
examination	O
status	O
,	O
stage	O
,	O
grade	O
,	O
primary	O
treatment	O
of	O
prostate	D
cancers	D
,	O
and	O
occurrence	O
of	O
other	O
cancers	D
were	O
compared	O
between	O
the	O
groups	O

RESULTS	O
:	O
The	O
mean	O
age	O
at	O
diagnosis	O
of	O
prostate	D
cancer	D
for	O
men	O
in	O
potentially	O
linked	O
families	O
was	O
significantly	O
lower	O
than	O
for	O
men	O
in	O
potentially	O
unlinked	O
families	O
(	O
63.7	O
vs	O
65.9	O
years	O
,	O
respectively	O
,	O
P=.01	O
;	O
mean	O
age	O
at	O
diagnosis	O
in	O
the	O
reference	O
population	O
was	O
71.6	O
years	O
)	O

Higher-grade	O
cancers	D
(	O
grade	O
3	O
)	O
were	O
more	O
common	O
in	O
potentially	O
linked	O
families	O
,	O
and	O
advanced-stage	O
disease	O
was	O
found	O
in	O
41	O
%	O
of	O
the	O
case	O
patients	O
in	O
potentially	O
linked	O
families	O
compared	O
with	O
31	O
%	O
in	O
both	O
the	O
potentially	O
unlinked	O
families	O
and	O
the	O
reference	O
groups	O
(	O
P=.03	O
for	O
the	O
latter	O
comparison	O
)	O

In	O
the	O
other	O
clinical	O
parameters	O
,	O
we	O
found	O
no	O
significant	O
differences	O
between	O
the	O
groups	O

A	O
modest	O
excess	O
of	O
breast	D
cancer	D
and	O
colon	D
cancer	D
was	O
found	O
in	O
potentially	O
linked	O
families	O
in	O
comparison	O
with	O
potentially	O
unlinked	O
families	O
,	O
but	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O

CONCLUSIONS	O
:	O
Families	O
that	O
provide	O
evidence	O
for	O
segregation	O
of	O
an	O
altered	O
HPC1	O
gene	O
are	O
characterized	O
by	O
multiple	O
cases	O
of	O
prostate	D
cancer	D
that	O
,	O
in	O
most	O
respects	O
,	O
are	O
indistinguishable	O
from	O
nonhereditary	O
cases	O

However	O
,	O
3	O
characteristics	O
were	O
observed	O
:	O
younger	O
age	O
at	O
diagnosis	O
,	O
higher-grade	O
tumors	D
,	O
and	O
more	O
advanced-stage	O
disease	O

Our	O
study	O
shows	O
that	O
a	O
significant	O
fraction	O
of	O
hereditary	O
prostate	D
cancers	D
are	O
diagnosed	O
in	O
advanced	O
stages	O
,	O
emphasizing	O
the	O
clinical	O
importance	O
of	O
early	O
detection	O
in	O
men	O
potentially	O
carrying	O
prostate	O
cancer	O
susceptibility	O
genes	O

These	O
findings	O
support	O
the	O
current	O
recommendations	O
to	O
screen	O
men	O
with	O
a	O
positive	O
family	O
history	O
of	O
prostate	D
cancer	D
beginning	O
at	O
age	O
40	O
years	O

CONTEXT	O
:	O
Susceptibility	O
to	O
multiple	D
sclerosis	D
(	D
MS	D
)	D
involves	O
a	O
genetically	O
complex	O
autoimmune	O
component	O

However	O
,	O
except	O
for	O
genes	O
in	O
the	O
HLA	O
system	O
,	O
specific	O
susceptibility	O
loci	O
are	O
unknown	O
or	O
unconfirmed	O

OBJECTIVE	O
:	O
To	O
investigate	O
several	O
loci	O
spanning	O
3	O
candidate	O
regions	O
for	O
a	O
role	O
in	O
multiple	D
sclerosis	D
(	D
MS	D
)	D
susceptibility	O
in	O
2	O
ethnic	O
groups	O
using	O
both	O
single-locus	O
and	O
haplotype	O
analyses	O

The	O
3	O
regions	O
include	O
HLA	O
on	O
chromosome	O
6p21.3	O
,	O
APOE	O
on	O
chromosome	O
19ql	O
3.2	O
,	O
and	O
MBP	O
(	O
myelin	O
basic	O
protein	O
)	O
on	O
chromosome	O
18q23	O

DESIGN	O
:	O
Case-control	O
association	O
testing	O

SUBJECTS	O
:	O
A	O
total	O
of	O
120	O
Caucasian	O
patients	O
with	O
MS	O
and	O
107	O
unrelated	O
control	O
individuals	O
from	O
California	O
,	O
and	O
32	O
patients	O
and	O
32	O
unrelated	O
control	O
individuals	O
from	O
Beijing	O
,	O
China	O

All	O
patients	O
with	O
MS	O
were	O
diagnosed	O
as	O
having	O
clinically	O
definite	O
disease	O
according	O
to	O
published	O
criteria	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Chi2	O
Testing	O
of	O
loci	O
and	O
individual	O
alleles	O
and	O
haplotypes	O

Haplotype	O
frequencies	O
were	O
estimated	O
with	O
standard	O
maximum	O
likelihood	O
methods	O

RESULTS	O
:	O
The	O
HLA	O
effect	O
is	O
due	O
to	O
the	O
class	O
II	O
DR2	O
haplotype	O
,	O
DRB1*1501-DQA1*0102-DRB1*0602	O
;	O
contributions	O
to	O
MS	O
susceptibility	O
from	O
additional	O
DRB1-DQB1	O
alleles	O
or	O
other	O
HLA	O
region	O
loci	O
were	O
not	O
observed	O

Variation	O
within	O
the	O
MBP	O
locus	O
on	O
chromosome	O
18q23	O
showed	O
no	O
effect	O
in	O
MS	O

The	O
distribution	O
of	O
haplotypes	O
from	O
5	O
loci	O
within	O
the	O
chromosome	O
19q13.2	O
region	O
,	O
including	O
D19S178	O
,	O
D19S574	O
,	O
APOE	O
,	O
APOC2	O
,	O
and	O
D19S219	O
,	O
differed	O
between	O
patient	O
and	O
control	O
samples	O

D19S574	O
showed	O
a	O
significant	O
effect	O
(	O
P=.015	O
)	O
in	O
Caucasian	O
patients	O
with	O
MS	O
due	O
to	O
the	O
increased	O
frequency	O
of	O
a	O
single	O
allele	O
(	O
P=.002	O
)	O

The	O
APOE	O
variation	O
,	O
prominent	O
in	O
other	O
neurological	O
diseases	O
,	O
showed	O
no	O
influence	O
on	O
MS	O
susceptibility	O
,	O
despite	O
its	O
location	O
within	O
the	O
chromosome	O
19q13.2	O
region	O

Interaction	O
effects	O
between	O
DR2	O
and	O
chromosome	O
19q13.2	O
or	O
MBP	O
in	O
MS	O
susceptibility	O
were	O
not	O
apparent	O

CONCLUSIONS	O
:	O
The	O
significant	O
chromosome	O
19q13.2	O
single-locus	O
and	O
multilocus	O
haplotype	O
associations	O
with	O
MS	O
in	O
Caucasian	O
and	O
Chinese	O
patient	O
samples	O
indicate	O
an	O
effect	O
from	O
a	O
nearby	O
disease	O
susceptibility	O
locus	O

These	O
initial	O
observations	O
are	O
an	O
encouraging	O
step	O
toward	O
the	O
description	O
of	O
non-HLA	O
genetic	O
susceptibility	O
to	O
MS	O

<	O
TO_SEE	O
>	O
CONTEXT	O
:	O
There	O
is	O
a	O
substantial	O
risk	O
of	O
a	O
second	O
cancer	O
for	O
persons	O
with	O
hereditary	O
retinoblastoma	O
,	O
which	O
is	O
enhanced	O
by	O
radiotherapy	O

<	O
TO_SEE	O
>	O
OBJECTIVE	O
:	O
To	O
examine	O
long-term	O
risk	O
of	O
new	O
primary	O
cancers	O
in	O
survivors	O
of	O
childhood	O
retinoblastoma	O
and	O
quantify	O
the	O
role	O
of	O
radiotherapy	O
in	O
sarcoma	O
development	O

DESIGN	O
:	O
Cohort	O
incidence	O
study	O
of	O
patients	O
with	O
retinoblastoma	O
followed	O
for	O
a	O
median	O
of	O
20	O
years	O
,	O
and	O
nested	O
case-control	O
study	O
of	O
a	O
radiation	O
dose-response	O
relationship	O
for	O
bone	O
and	O
soft	O
tissue	O
sarcomas	O

SETTING/PARTICIPANTS	O
:	O
A	O
total	O
of	O
1604	O
patients	O
with	O
retinoblastoma	D
who	O
survived	O
at	O
least	O
1	O
year	O
after	O
diagnosis	O
,	O
identified	O
from	O
hospital	O
records	O
in	O
Massachusetts	O
and	O
New	O
York	O
during	O
1914	O
to	O
1984	O

RESULTS	O
:	O
Incidence	O
of	O
subsequent	O
cancers	D
was	O
statistically	O
significantly	O
elevated	O
only	O
in	O
the	O
961	O
patients	O
with	O
hereditary	O
retinoblastoma	D
,	O
in	O
whom	O
190	O
cancers	D
were	O
diagnosed	O
,	O
vs	O
6.3	O
expected	O
in	O
the	O
general	O
population	O
(	O
relative	O
risk	O
(	O
RR	O
)	O
,	O
30	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
26-47	O
)	O
)	O

Cumulative	O
incidence	O
(	O
+/-SE	O
)	O
of	O
a	O
second	O
cancer	D
at	O
50	O
years	O
after	O
diagnosis	O
was	O
51.0	O
%	O
(	O
+/-6.2	O
%	O
)	O
for	O
hereditary	O
retinoblastoma	D
,	O
and	O
5.0	O
%	O
(	O
+/-3.0	O
%	O
)	O
for	O
nonhereditary	O
retinoblastoma	D

All	O
114	O
sarcomas	D
of	O
diverse	O
histologic	O
types	O
occurred	O
in	O
patients	O
with	O
hereditary	O
retinoblastoma	D

For	O
soft	O
tissue	O
sarcomas	D
,	O
the	O
RRs	O
showed	O
a	O
stepwise	O
increase	O
at	O
all	O
dose	O
categories	O
,	O
and	O
were	O
statistically	O
significant	O
at	O
10	O
to	O
29.9	O
Gy	O
and	O
30	O
to	O
59.9	O
Gy	O

A	O
radiation	O
risk	O
for	O
all	O
sarcomas	O
combined	O
was	O
evident	O
at	O
doses	O
above	O
5	O
Gy	O
,	O
rising	O
to	O
10.7-fold	O
at	O
doses	O
of	O
60	O
Gy	O
or	O
greater	O
(	O
P	O
&	O
#	O
60	O
;	O
.05	O
)	O

<	O
TO_SEE	O
>	O
CONCLUSIONS	O
:	O
Genetic	O
predisposition	O
has	O
a	O
substantial	O
impact	O
on	O
risk	O
of	O
subsequent	D
cancers	D
in	O
retinoblastoma	D
patients	O
,	O
which	O
is	O
further	O
increased	O
by	O
radiation	T
treatment	T

A	O
radiation	O
dose-response	O
relationship	O
is	O
demonstrated	O
for	O
all	O
sarcomas	O
and	O
,	O
for	O
the	O
first	O
time	O
in	O
humans	O
,	O
for	O
soft	O
tissue	O
sarcomas	O

Retinoblastoma	D
patients	O
should	O
be	O
examined	O
for	O
new	O
cancers	D
and	O
followed	O
into	O
later	O
life	O
to	O
determine	O
whether	O
their	O
extraordinary	O
cancer	O
risk	O
extends	O
to	O
common	O
cancers	D
of	O
adulthood	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
rate	O
of	O
recent	O
cocaine	O
use	O
among	O
a	O
metropolitan	O
population	O
of	O
predominantly	O
Hispanic	O
and	O
African-American	O
women	O
with	O
preterm	O
premature	D
rupture	D
of	D
the	D
membranes	D
(	D
PROM	D
)	D
and	O
to	O
ascertain	O
the	O
impact	O
of	O
cocaine	O
on	O
the	O
latency	O
period	O
between	O
rupture	O
of	O
membranes	O
and	O
delivery	O

Urine	O
toxicology	O
screens	O
were	O
prospectively	O
obtained	O
on	O
147	O
women	O
with	O
preterm	D
PROM	D

The	O
urine	O
screen	O
did	O
not	O
influence	O
management	O
decisions	O

All	O
women	O
were	O
expectantly	O
managed	O
without	O
tocolytics	O
until	O
37	O
weeks	O
'	O
gestation	O
unless	O
they	O
developed	O
clinical	O
chorioamnionitis	O
,	O
or	O
nonreassuring	O
fetal	O
heart	O
rate	O
tracing	O
or	O
biophysical	O
profile	O

Demographic	O
information	O
,	O
hours	O
from	O
rupture	O
of	O
membranes	O
to	O
delivery	O
,	O
gestational	O
age	O
,	O
and	O
birth	O
weight	O
at	O
delivery	O
were	O
compared	O
using	O
Fisher	O
's	O
exact	O
,	O
Mann-Whitney	O
U	O
,	O
and	O
randomization	O
tests	O
where	O
appropriate	O

The	O
rate	O
of	O
positive	O
urine	O
drug	O
screens	O
for	O
cocaine	O
was	O
8.2	O
%	O

Women	O
in	O
the	O
cocaine	O
positive	O
group	O
were	O
of	O
higher	O
parity	O
(	O
3	O
,	O
(	O
0-7	O
)	O
vs.	O
1	O
,	O
(	O
0-6	O
)	O
,	O
p	O
=	O
0.001	O
)	O
and	O
tended	O
to	O
be	O
older	O
(	O
27	O
,	O
(	O
23-42	O
)	O
vs.	O
25	O
,	O
(	O
14-40	O
)	O
)	O

There	O
was	O
a	O
higher	O
rate	O
of	O
recent	O
cocaine	O
use	O
among	O
African-American	O
women	O
(	O
20.4	O
%	O
)	O
as	O
compared	O
to	O
non-African-Americans	O
(	O
1.2	O
%	O
,	O
p	O
=	O
0.0001	O
)	O

Cocaine-positive	O
women	O
presented	O
at	O
an	O
earlier	O
gestational	O
age	O
(	O
32	O
weeks	O
'	O
,	O
(	O
24-34	O
)	O
vs.	O
33	O
weeks	O
'	O
,	O
(	O
23-36	O
)	O
,	O
p	O
=	O
0.02	O
)	O
and	O
had	O
a	O
significantly	O
longer	O
membrane	O
rupture	O
to	O
delivery	O
interval	O
than	O
women	O
with	O
a	O
negative	O
urine	O
drug	O
screen	O
(	O
174	O
hr	O
,	O
(	O
6-475	O
)	O
vs.	O
33	O
hours	O
(	O
1-833	O
)	O
,	O
p	O
=	O
0.01	O
)	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
reason	O
for	O
delivery	O
between	O
the	O
two	O
groups	O
of	O
patients	O

Recent	O
cocaine	O
use	O
among	O
women	O
with	O
preterm	D
PROM	D
is	O
common	O
in	O
only	O
some	O
segments	O
of	O
an	O
urban	O
population	O

Women	O
with	O
recent	O
cocaine	O
use	O
present	O
with	O
ruptured	O
membranes	O
at	O
an	O
earlier	O
gestational	O
age	O
and	O
may	O
actually	O
have	O
a	O
longer	O
latency	O
period	O
than	O
women	O
who	O
do	O
not	O
use	O
cocaine	O

The	O
objective	O
of	O
this	O
article	O
is	O
to	O
explore	O
attitudes	O
of	O
an	O
inner-city	O
,	O
pregnant	O
cohort	O
about	O
general	O
and	O
HIV-related	O
prenatal	O
care	O

Responses	O
to	O
an	O
interview	O
at	O
initial	O
prenatal	O
care	O
enrollment	O
were	O
compared	O
using	O
Chi-square	O
and	O
Fisher	O
's	O
exact	O
tests	O

Of	O
75	O
women	O
,	O
drug	O
users	O
(	O
51	O
%	O
)	O
were	O
more	O
likely	O
to	O
say	O
that	O
they	O
would	O
defer	O
initiating	O
prenatal	O
care	O
(	O
P	O
=	O
0.03	O
)	O
and	O
to	O
minimize	O
the	O
risk	O
of	O
drug	O
or	O
alcohol	O
use	O
to	O
the	O
fetus	O
(	O
P	O
=	O
0.04	O
)	O

Most	O
(	O
85	O
%	O
)	O
viewed	O
pregnancy	O
as	O
inappropriate	O
for	O
HIV	D
infected	O
women	O
and	O
primarily	O
drug	O
users	O
(	O
P	O
=	O
0.06	O
)	O
would	O
abort	O
if	O
HIV	D
infected	O

Over	O
half	O
thought	O
HIV	D
transmission	O
occurred	O
most	O
times	O
or	O
always	O

Only	O
20	O
%	O
had	O
heard	O
of	O
a	O
drug	O
to	O
reduce	O
this	O
risk	O
,	O
but	O
95	O
%	O
would	O
take	O
such	O
a	O
therapy	O

These	O
inner-city	O
,	O
pregnant	O
women	O
disapproved	O
of	O
pregnancy	O
if	O
HIV	D
infected	O
and	O
thought	O
the	O
risk	O
of	O
transmission	O
was	O
high	O

They	O
knew	O
little	O
of	O
how	O
to	O
reduce	O
this	O
risk	O
but	O
nearly	O
all	O
would	O
accept	O
a	O
drug	O
to	O
prevent	O
transmission	O

The	O
association	O
of	O
parvovirus	D
B19	D
infection	D
and	O
hydrops	D
fetalis	D
is	O
well	O
known	O

However	O
,	O
the	O
association	O
of	O
parvovirus	D
and	O
fetal	O
pleural	O
or	O
pericardial	D
effusions	D
has	O
not	O
been	O
reported	O

We	O
present	O
five	O
cases	O
of	O
isolated	O
pleural	O
or	O
pericardial	D
effusion	D
with	O
documented	O
maternal	O
parvovirus	D
infection	D
in	O
four	O
of	O
these	O
pregnancies	O

In	O
the	O
absence	O
of	O
structural	O
or	O
karyotypic	O
abnormalities	O
,	O
spontaneous	O
resolution	O
of	O
the	O
effusion	O
portends	O
for	O
a	O
successful	O
pregnancy	O
outcome	O

BACKGROUND	O
:	O
Cochlear	T
implantation	T
is	O
nowadays	O
a	O
reliable	O
and	O
well-accepted	O
method	O
of	O
auditory	O
rehabilitation	O
in	O
selected	O
adults	O
and	O
children	O

METHODS	O
:	O
We	O
present	O
rehabilitation	O
data	O
on	O
21	O
adult	O
patients	O
provided	O
with	O
the	O
Nucleus	O
CI22	O
M	O
cochlear	O
implant	O
using	O
the	O
SPEAK	O
strategy	O

RESULTS	O
:	O
Results	O
of	O
first	O
tune-up	O
show	O
an	O
open	O
set	O
speech	O
understanding	O
in	O
approximately	O
50	O
%	O
of	O
patients	O

Long-term	O
results	O
also	O
reveal	O
further	O
improvement	O
in	O
patients	O
who	O
had	O
no	O
open	O
set	O
speech	O
understanding	O

Our	O
data	O
seem	O
to	O
indicate	O
similar	O
results	O
in	O
comparison	O
to	O
other	O
groups	O
using	O
the	O
CIS	O
strategy	O

CONCLUSIONS	O
:	O
In	O
adults	O
,	O
open	O
set	O
speech	O
understanding	O
can	O
be	O
achieved	O
even	O
at	O
the	O
first	O
tune-up	O

Results	O
of	O
early	O
rehabilitation	O
seem	O
to	O
be	O
influenced	O
by	O
duration	O
and	O
etiology	O
of	O
deafness	D
,	O
experience	O
with	O
hearing	O
aids	O
,	O
and	O
other	O
factors	O

Adverse	O
drug	O
effects	O
are	O
manifold	O
and	O
heterogenous	O

Many	O
situations	O
may	O
hamper	O
the	O
signalling	O
(	O
i.e	O
.	O
the	O
detection	O
of	O
early	O
warning	O
signs	O
)	O
of	O
adverse	O
effects	O
and	O
new	O
signals	O
often	O
differ	O
from	O
previous	O
experiences	O

Signals	O
have	O
qualitative	O
and	O
quantitative	O
aspects	O

Different	O
categories	O
of	O
adverse	O
effects	O
need	O
different	O
methods	O
for	O
detection	O

Current	O
pharmacovigilance	O
is	O
predominantly	O
based	O
on	O
spontaneous	O
reporting	O
and	O
is	O
mainly	O
helpful	O
in	O
detecting	O
type	O
B	O
effects	O
(	O
those	O
effects	O
that	O
are	O
often	O
allergic	O
or	O
idiosyncratic	O
reactions	O
,	O
characteristically	O
occurring	O
in	O
only	O
a	O
minority	O
of	O
patients	O
and	O
usually	O
unrelated	O
to	O
dosage	O
and	O
that	O
are	O
serious	O
,	O
unexpected	O
and	O
unpredictable	O
)	O
and	O
unusual	O
type	O
A	O
effects	O
(	O
those	O
effects	O
that	O
are	O
related	O
to	O
the	O
pharmacological	O
effects	O
of	O
the	O
drug	O
and	O
are	O
dosage-related	O
)	O

Examples	O
of	O
other	O
sources	O
of	O
signals	O
are	O
prescription	O
event	O
monitoring	O
,	O
large	O
automated	O
data	O
resources	O
on	O
morbidity	O
and	O
drug	O
use	O
(	O
including	O
record	O
linkage	O
)	O
,	O
case-control	O
surveillance	O
and	O
follow-up	O
studies	O

Type	O
C	O
effects	O
(	O
those	O
effects	O
related	O
to	O
an	O
increased	O
frequency	O
of	O
'spontaneous	O
'	O
disease	O
)	O
are	O
difficult	O
to	O
study	O
,	O
however	O
,	O
and	O
continue	O
to	O
pose	O
a	O
pharmacoepidemiological	O
challenge	O

Seven	O
basic	O
considerations	O
can	O
be	O
identified	O
that	O
determine	O
the	O
evidence	O
contained	O
in	O
a	O
signal	O
:	O
quantitative	O
strength	O
of	O
the	O
association	O
,	O
consistency	O
of	O
the	O
data	O
,	O
exposure	O
response	O
relationship	O
,	O
biological	O
plausibility	O
,	O
experimental	O
findings	O
,	O
possible	O
analogies	O
and	O
the	O
nature	O
and	O
quality	O
of	O
the	O
data	O

A	O
proposal	O
is	O
made	O
for	O
a	O
standard	O
signal	O
management	O
procedure	O
at	O
pharmacovigilance	O
centres	O
,	O
including	O
the	O
following	O
steps	O
:	O
signal	O
delineation	O
,	O
literature	O
search	O
,	O
preliminary	O
inventory	O
of	O
data	O
,	O
collection	O
of	O
additional	O
information	O
,	O
consultation	O
with	O
the	O
World	O
Health	O
Organization	O
Centre	O
for	O
International	O
Drug	O
Monitoring	O
and	O
the	O
relevant	O
drug	O
companies	O
,	O
aggregated	O
data	O
assessment	O
and	O
a	O
report	O
in	O
writing	O

A	O
better	O
understanding	O
of	O
the	O
conditions	O
and	O
mechanisms	O
involved	O
in	O
the	O
detection	O
of	O
adverse	O
drug	O
effects	O
may	O
further	O
improve	O
strategies	O
for	O
pharmacovigilance	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
safety	O
and	O
efficacy	O
of	O
methylphenidate	T
in	O
children	O
with	O
the	O
dual	O
diagnosis	O
of	O
epilepsy	D
and	O
attention	D
deficit	D
hyperactivity	D
disorder	D
(	D
ADHD	D
)	D

STUDY	O
DESIGN	O
:	O
Thirty	O
children	O
,	O
aged	O
6.4	O
to	O
16.4	O
years	O
,	O
with	O
epilepsy	D
and	O
ADHD	D
were	O
studied	O
during	O
a	O
4-month	O
period	O

During	O
the	O
initial	O
2	O
months	O
of	O
the	O
study	O
,	O
the	O
children	O
were	O
treated	O
with	O
antiepileptic	T
drugs	T
(	T
AEDs	T
)	T
only	O
,	O
and	O
for	O
the	O
remaining	O
2	O
months	O
,	O
methylphenidate	T
was	O
added	O
at	O
a	O
morning	O
dose	O
of	O
0.3	O
mg/kg	O

They	O
underwent	O
neurologic	O
assessment	O
,	O
brain	O
computed	O
tomography	O
,	O
IQ	O
testing	O
,	O
and	O
assessment	O
with	O
the	O
Childhood	O
Behavior	O
Checklist	O
at	O
baseline	O
before	O
methylphenidate	T
therapy	T

Electroencephalography	O
,	O
AED	O
determinations	O
,	O
and	O
the	O
continuous-performance	O
task	O
(	O
CPT	O
)	O
test	O
were	O
done	O
at	O
baseline	O
and	O
after	O
2	O
months	O
of	O
methylphenidate	O
therapy	O

A	O
double-blind	O
,	O
crossover	O
design	O
was	O
used	O
to	O
compare	O
the	O
effects	O
of	O
methylphenidate	T
versus	O
placebo	O
on	O
an	O
electroencephalogram	O
,	O
AED	O
levels	O
,	O
and	O
the	O
CPT	O

On	O
the	O
2	O
days	O
of	O
testing	O
,	O
the	O
child	O
received	O
AEDs	T
and	O
a	O
capsule	O
containing	O
either	O
placebo	O
or	O
methylphenidate	T

RESULTS	O
:	O
None	O
of	O
the	O
25	O
children	O
of	O
this	O
sample	O
who	O
were	O
seizure	O
free	O
had	O
attacks	O
while	O
taking	O
methylphenidate	O

Of	O
the	O
5	O
children	O
with	O
seizures	D
,	O
3	O
had	O
an	O
increase	O
in	O
attacks	O
,	O
whereas	O
the	O
other	O
2	O
showed	O
no	O
change	O
or	O
a	O
reduction	O

There	O
were	O
no	O
significant	O
changes	O
in	O
AED	O
levels	O
or	O
electroencephalographic	O
findings	O

Methylphenidate	T
benefited	O
70	O
%	O
of	O
children	O
according	O
to	O
parental	O
report	O
;	O
methylphenidate	T
also	O
enhanced	O
performance	O
on	O
the	O
CPT	O

Side	O
effects	O
of	O
methylphenidate	T
were	O
mild	O
and	O
transient	O

CONCLUSION	O
:	O
Methylphenidate	T
is	O
effective	O
in	O
treating	O
children	O
with	O
epilepsy	D
and	O
ADHD	D
and	O
safe	O
in	O
children	O
who	O
are	O
seizure	O
free	O

Caution	O
is	O
warranted	O
for	O
those	O
still	O
having	O
seizures	O
while	O
receiving	O
AED	O
therapy	O

The	O
temporal	O
properties	O
of	O
semantic	O
and	O
phonological	O
processes	O
in	O
speech	O
production	O
were	O
investigated	O
in	O
a	O
new	O
experimental	O
paradigm	O
using	O
movement-related	O
brain	O
potentials	O

The	O
main	O
experimental	O
task	O
was	O
picture	O
naming	O

In	O
addition	O
,	O
a	O
2-choice	O
reaction	O
go/no-go	O
procedure	O
was	O
included	O
,	O
involving	O
a	O
semantic	O
and	O
a	O
phonological	O
categorization	O
of	O
the	O
picture	O
name	O

Lateralized	O
readiness	O
potentials	O
(	O
LRPs	O
)	O
were	O
derived	O
to	O
test	O
whether	O
semantic	O
and	O
phonological	O
information	O
activated	O
motor	O
processes	O
at	O
separate	O
moments	O
in	O
time	O

An	O
LRP	O
was	O
only	O
observed	O
on	O
no-go	O
trials	O
when	O
the	O
semantic	O
(	O
not	O
the	O
phonological	O
)	O
decision	O
determined	O
the	O
response	O
hand	O

Varying	O
the	O
position	O
of	O
the	O
critical	O
phoneme	O
in	O
the	O
picture	O
name	O
did	O
not	O
affect	O
the	O
onset	O
of	O
the	O
LRP	O
but	O
rather	O
influenced	O
when	O
the	O
LRP	O
began	O
to	O
differ	O
on	O
go	O
and	O
no-go	O
trials	O
and	O
allowed	O
the	O
duration	O
of	O
phonological	O
encoding	O
of	O
a	O
word	O
to	O
be	O
estimated	O

These	O
results	O
provide	O
electrophysiological	O
evidence	O
for	O
early	O
semantic	O
activation	O
and	O
later	O
phonological	O
encoding	O

The	O
effects	O
of	O
alanine	O
and	O
glycine	O
substitution	O
for	O
tryptophan	O
upon	O
the	O
species	O
heterogeneity	O
of	O
gramicidin	O
A	O
analogs	O
incorporated	O
into	O
SDS	O
micelles	O
have	O
been	O
investigated	O

The	O
sequential	O
replacement	O
of	O
the	O
four	O
tryptophan	O
residues	O
in	O
gramicidin	O
A	O
at	O
positions	O
15	O
,	O
13	O
,	O
11	O
,	O
and	O
9	O
with	O
glycine	O
showed	O
that	O
there	O
was	O
no	O
detectable	O
effect	O
at	O
position	O
15	O
but	O
increasing	O
heterogeneity	O
of	O
species	O
in	O
the	O
micelles	O
proceeding	O
toward	O
the	O
interior	O
of	O
the	O
micelle	O
at	O
position	O
9	O

The	O
replacement	O
of	O
tryptophan	O
at	O
positions	O
15	O
and	O
9	O
with	O
alanine	O
was	O
found	O
to	O
produce	O
more	O
species	O
heterogeneity	O
than	O
found	O
with	O
glycine	O
substitution	O
at	O
the	O
same	O
positions	O

An	O
increase	O
in	O
the	O
SDS	O
concentration	O
reduces	O
the	O
number	O
of	O
different	O
species	O
present	O
in	O
micelles	O

With	O
the	O
Gly-11	O
,	O
Gly-13	O
,	O
and	O
Gly-15	O
analogs	O
,	O
the	O
increase	O
in	O
SDS	O
concentration	O
results	O
in	O
the	O
formation	O
of	O
a	O
single	O
species	O
;	O
however	O
,	O
for	O
the	O
Gly-9	O
,	O
Ala-9	O
,	O
and	O
Ala-15	O
analogs	O
,	O
heterogeneity	O
remains	O

Molecular	O
dynamics	O
in	O
torsion-angle	O
space	O
was	O
applied	O
to	O
nuclear	O
magnetic	O
resonance	O
structure	O
calculation	O
using	O
nuclear	O
Overhauser	O
effect-derived	O
distances	O
and	O
J-coupling-constant-derived	O
dihedral	O
angle	O
restraints	O

Compared	O
to	O
two	O
other	O
commonly	O
used	O
algorithms	O
,	O
molecular	O
dynamics	O
in	O
Cartesian	O
space	O
and	O
metric-matrix	O
geometry	O
combined	O
with	O
Cartesian	O
molecular	O
dynamics	O
,	O
the	O
method	O
shows	O
increased	O
computational	O
efficiency	O
and	O
success	O
rate	O
for	O
large	O
proteins	O
,	O
and	O
it	O
shows	O
a	O
dramatically	O
increased	O
radius	O
of	O
convergence	O
for	O
DNA	O

The	O
torsion-angle	O
molecular	O
dynamics	O
algorithm	O
starts	O
from	O
an	O
extended	O
strand	O
conformation	O
and	O
proceeds	O
in	O
four	O
stages	O
:	O
high-temperature	O
torsion-angle	O
molecular	O
dynamics	O
,	O
slow-cooling	O
torsion-angle	O
molecular	O
dynamics	O
,	O
Cartesian	O
molecular	O
dynamics	O
,	O
and	O
minimization	O

Tests	O
were	O
carried	O
out	O
using	O
experimental	O
NMR	O
data	O
for	O
protein	O
G	O
,	O
interleukin-8	O
,	O
villin	O
14T	O
,	O
and	O
a	O
12	O
base-pair	O
duplex	O
of	O
DNA	O
,	O
and	O
simulated	O
NMR	O
data	O
for	O
bovine	O
pancreatic	O
trypsin	O
inhibitor	O

For	O
villin	O
14T	O
,	O
a	O
monomer	O
consisting	O
of	O
126	O
residues	O
,	O
structure	O
determination	O
by	O
torsion-angle	O
molecular	O
dynamics	O
has	O
a	O
success	O
rate	O
of	O
85	O
%	O
,	O
a	O
more	O
than	O
twofold	O
improvement	O
over	O
other	O
methods	O

In	O
the	O
case	O
of	O
the	O
12	O
base-pair	O
DNA	O
duplex	O
,	O
torsion-angle	O
molecular	O
dynamics	O
had	O
a	O
success	O
rate	O
of	O
52	O
%	O
while	O
Cartesian	O
molecular	O
dynamics	O
and	O
metric-matrix	O
distance	O
geometry	O
always	O
failed	O

The	O
wavelet-transform	O
method	O
is	O
used	O
to	O
quantify	O
the	O
magnetic	O
resonance	O
spectroscopy	O
(	O
MRS	O
)	O
parameters	O
:	O
chemical	O
shift	O
,	O
apparent	O
relaxation	O
time	O
T2	O
,	O
resonance	O
amplitude	O
,	O
and	O
phase	O

Wavelet	O
transformation	O
is	O
a	O
time-frequency	O
representation	O
which	O
separates	O
each	O
component	O
from	O
the	O
FID	O
,	O
then	O
successively	O
quantifies	O
it	O
and	O
subtracts	O
it	O
from	O
the	O
raw	O
signal	O

Two	O
iterative	O
procedures	O
have	O
been	O
developed	O

They	O
have	O
been	O
combined	O
with	O
a	O
nonlinear	O
regression	O
analysis	O
method	O
and	O
tested	O
on	O
both	O
simulated	O
and	O
real	O
sets	O
of	O
biomedical	O
MRS	O
data	O
selected	O
with	O
respect	O
to	O
the	O
main	O
problems	O
usually	O
encountered	O
in	O
quantifying	O
biomedical	O
MRS	O
,	O
specifically	O
``	O
chemical	O
noise	O
,	O
''	O
resulting	O
from	O
overlapping	O
resonances	O
,	O
and	O
baseline	O
distortion	O

The	O
results	O
indicate	O
that	O
the	O
wavelet-transform	O
method	O
can	O
provide	O
efficient	O
and	O
accurate	O
quantification	O
of	O
MRS	O
data	O

BACKGROUND	O
:	O
Antiplatelet	T
therapy	T
with	T
aspirin	T
and	T
systematic	T
anticoagulation	T
with	T
warfarin	T
reduce	O
cardiovascular	D
morbidity	D
and	D
mortality	D
after	D
myocardial	D
infarction	D
when	O
given	O
alone	O

In	O
the	O
Coumadin	O
Aspirin	O
Reinfarction	O
Study	O
(	O
CARS	O
)	O
,	O
we	O
aimed	O
to	O
find	O
out	O
whether	O
a	O
combination	O
of	O
low-dose	O
warfarin	T
and	O
low-dose	T
aspirin	T
would	O
give	O
superior	O
results	O
to	O
standard	O
aspirin	T
monotherapy	T
without	O
excessive	O
bleeding	O
risk	O

METHODS	O
:	O
We	O
used	O
a	O
randomised	O
double-blind	O
study	O
design	O

At	O
293	O
sites	O
,	O
we	O
randomly	O
assigned	O
8803	O
patients	O
who	O
had	O
had	O
myocardial	D
infarction	D
,	O
treatment	O
with	O
160	T
mg	T
aspirin	T
,	O
3	T
mg	T
warfarin	T
with	T
80	T
mg	T
aspirin	T
,	O
or	O
1	T
mg	T
warfarin	T
with	T
80	T
mg	T
aspirin	T

Patients	O
took	O
a	O
single	O
tablet	O
daily	O
,	O
and	O
attended	O
for	O
prothrombin	O
time	O
(	O
PT	O
)	O
measurements	O
at	O
weeks	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
and	O
12	O
,	O
and	O
then	O
every	O
3	O
months	O

Patients	O
were	O
followed	O
up	O
for	O
a	O
maximum	O
of	O
33	O
months	O
(	O
median	O
14	O
months	O
)	O

FINDINGS	O
:	O
The	O
primary	O
event	O
was	O
first	O
occurrence	O
of	O
reinfarction	O
,	O
non-fatal	O
ischaemic	D
stroke	D
,	O
or	O
cardiovascular	O
death	O

1-year	O
life-table	O
estimates	O
for	O
the	O
primary	O
event	O
were	O
8.6	O
%	O
(	O
95	O
%	O
CI	O
7.6-9.6	O
)	O
for	O
160	O
mg	O
aspirin	T
,	O
8.4	O
%	O
(	O
7.4-9.4	O
)	O
for	O
3	O
mg	O
warfarin	T
with	O
80	O
mg	O
aspirin	T
,	O
and	O
8.8	O
%	O
(	O
7.6-10	O
)	O
for	O
1	O
mg	O
warfarin	T
with	O
80	O
mg	O
aspirin	T

Primary	O
comparisons	O
were	O
done	O
with	O
all	O
follow-up	O
data	O

The	O
relative	O
risk	O
of	O
the	O
primary	O
event	O
for	O
the	O
160	O
mg	O
aspirin	O
group	O
compared	O
with	O
the	O
3	O
mg	O
warfarin	O
with	O
80	O
mg	O
aspirin	O
group	O
was	O
0.95	O
(	O
0.81-1.12	O
,	O
p	O
=	O
0.57	O
)	O

For	O
spontaneous	O
major	O
haemorrhage	O
(	O
not	O
procedure	O
related	O
)	O
,	O
1-year	O
life-table	O
estimates	O
were	O
0.74	O
%	O
(	O
0.43-1.1	O
)	O
in	O
the	O
160	O
mg	O
aspirin	O
group	O
and	O
1.4	O
%	O
(	O
0.94-1.8	O
)	O
in	O
the	O
3	O
mg	O
warfarin	O
with	O
80	O
mg	O
aspirin	O
group	O
(	O
p	O
=	O
0.014	O
log	O
rank	O
on	O
follow-up	O
)	O

For	O
the	O
3382	O
patients	O
assigned	O
3	O
mg	O
warfarin	T
with	O
80	O
mg	O
aspirin	T
,	O
the	O
INR	O
results	O
were	O
:	O
at	O
week	O
1	O
(	O
n	O
=	O
2985	O
)	O
median	O
1.51	O
(	O
IQR	O
1.23-2.13	O
)	O
;	O
at	O
week	O
4	O
(	O
n	O
=	O
2701	O
)	O
1.27	O
(	O
1.13-1.64	O
)	O
;	O
at	O
month	O
6	O
(	O
n	O
=	O
2145	O
)	O
1.19	O
(	O
1.08-1.44	O
)	O

INTERPRETATION	O
:	O
Low	O
,	O
fixed-dose	O
warfarin	T
(	T
1	T
mg	T
or	T
3	T
mg	T
)	T
combined	T
with	T
low-dose	T
aspirin	T
(	T
80	T
mg	T
)	T
in	O
patients	O
who	O
have	O
had	O
myocardial	D
infarction	D
does	O
not	O
provide	O
clinical	O
benefit	O
beyond	O
that	O
achievable	O
with	O
160	O
mg	O
aspirin	T
monotherapy	T

BACKGROUND	O
:	O
There	O
is	O
serological	O
evidence	O
for	O
an	O
association	O
between	O
Chlamydia	D
pneumoniae	D
and	O
coronary	D
heart	D
disease	D

We	O
investigated	O
the	O
hypothesis	O
that	O
an	T
antichlamydial	T
macrolide	T
antibiotic	T
,	T
roxithromycin	T
,	O
can	O
prevent	O
or	O
reduce	O
recurrent	O
major	O
ischaemic	O
events	O
in	O
patients	O
with	O
unstable	D
angina	D

METHODS	O
:	O
The	O
effect	O
of	O
roxithromycin	T
was	O
assessed	O
in	O
a	O
double-blind	O
,	O
randomised	O
,	O
prospective	O
,	O
multicentre	O
,	O
parallel-group	O
,	O
placebo-controlled	O
pilot	O
study	O
of	O
202	O
patients	O
with	O
unstable	D
angina	D
or	O
non-Q-wave	D
myocardial	D
infarction	D

Patients	O
were	O
randomly	O
assigned	O
either	O
roxithromycin	T
150	O
mg	O
orally	O
twice	O
a	O
day	O
(	O
n	O
=	O
102	O
)	O
or	O
placebo	O
orally	O
twice	O
a	O
day	O
(	O
n	O
=	O
100	O
)	O

The	O
treatment	O
was	O
for	O
30	O
days	O

Patients	O
were	O
followed	O
up	O
for	O
6	O
months	O

We	O
report	O
the	O
primary	O
clinical	O
endpoints	O
(	O
cardiac	D
ischaemic	D
death	D
,	O
myocardial	D
infarction	D
,	O
and	O
severe	O
recurrent	O
ischaemia	D
)	O
,	O
assessed	O
at	O
day	O
31	O
,	O
in	O
202	O
patients	O
on	O
an	O
intention-to-treat	O
basis	O

FINDINGS	O
:	O
A	O
statistically	O
significant	O
reduction	O
in	O
the	O
primary	O
composite	O
triple	O
endpoint	O
rates	O
was	O
observed	O
in	O
the	O
roxithromycin	O
group	O
:	O
p	O
=	O
0.032	O

The	O
rate	O
of	O
severe	O
recurrent	O
ischaemia	O
,	O
myocardial	O
infarction	O
,	O
and	O
ischaemic	O
death	O
was	O
5.4	O
%	O
,	O
2.2	O
%	O
,	O
and	O
2.2	O
%	O
in	O
the	O
placebo	O
group	O
and	O
1.1	O
%	O
,	O
0	O
%	O
,	O
and	O
0	O
%	O
,	O
in	O
the	O
roxithromycin	O
group	O
,	O
respectively	O

No	O
major	O
drug-related	O
adverse	O
effects	O
were	O
observed	O

INTERPRETATION	O
:	O
Antichlamydial	T
antibiotics	T
may	O
be	O
useful	O
in	O
therapeutic	O
intervention	O
in	O
addition	O
to	O
standard	O
medication	O
in	O
patients	O
with	O
coronary-artery	D
disease	D

Large-scale	O
trials	O
are	O
needed	O
to	O
confirm	O
these	O
preliminary	O
observations	O

BACKGROUND	O
:	O
Stage	D
Ib	D
and	D
IIa	D
cervical	D
carcinoma	D
can	O
be	O
cured	O
by	O
radical	T
surgery	T
or	O
radiotherapy	T

These	O
two	O
procedures	O
are	O
equally	O
effective	O
,	O
but	O
differ	O
in	O
associated	O
morbidity	O
and	O
type	O
of	O
complications	O

In	O
this	O
prospective	O
randomised	O
trial	O
of	O
radiotherapy	T
versus	O
surgery	T
,	O
our	O
aim	O
was	O
to	O
assess	O
the	O
5-year	O
survival	O
and	O
the	O
rate	O
and	O
pattern	O
of	O
complications	O
and	O
recurrences	O
associated	O
with	O
each	O
treatment	O

METHODS	O
:	O
Between	O
September	O
,	O
1986	O
,	O
and	O
December	O
,	O
1991	O
,	O
469	O
women	O
with	O
newly	O
diagnosed	O
stage	O
Ib	O
and	O
IIa	O
cervical	T
carcinoma	T
were	O
referred	O
to	O
our	O
institute	O

343	O
eligible	O
patients	O
were	O
randomised	O
:	O
172	O
to	O
surgery	T
and	O
171	O
to	O
radical	O
radiotherapy	T

Adjuvant	O
radiotherapy	O
was	O
delivered	O
after	O
surgery	O
for	O
women	O
with	O
surgical	O
stage	O
pT2b	O
or	O
greater	O
,	O
less	O
than	O
3	O
mm	O
of	O
safe	O
cervical	O
stroma	O
,	O
cut-through	O
,	O
or	O
positive	O
nodes	O

The	O
primary	O
outcome	O
measures	O
were	O
5-year	O
survival	O
and	O
the	O
rate	O
of	O
complications	O

The	O
analysis	O
of	O
survival	O
and	O
recurrence	O
was	O
by	O
intention	O
to	O
treat	O
and	O
analysis	O
of	O
complications	O
was	O
by	O
treatment	O
delivered	O

FINDINGS	O
:	O
170	O
patients	O
in	O
the	O
surgery	O
group	O
and	O
167	O
in	O
the	O
radiotherapy	O
group	O
were	O
included	O
in	O
the	O
intention-to-treat	O
analysis	O
;	O
scheduled	O
treatment	O
was	O
delivered	O
to	O
169	O
and	O
158	O
women	O
,	O
respectively	O
,	O
62	O
of	O
114	O
women	O
with	O
cervical	O
diameters	O
of	O
4	O
cm	O
or	O
smaller	O
and	O
46	O
of	O
55	O
with	O
diameters	O
larger	O
than	O
4	O
cm	O
received	O
adjuvant	O
therapy	O

After	O
a	O
median	O
follow-up	O
of	O
87	O
(	O
range	O
57-120	O
)	O
months	O
,	O
5-year	O
overall	O
and	O
disease-free	O
survival	O
were	O
identical	O
in	O
the	O
surgery	O
and	O
radiotherapy	O
groups	O
(	O
83	O
%	O
and	O
74	O
%	O
,	O
respectively	O
,	O
for	O
both	O
groups	O
)	O
,	O
86	O
women	O
developed	O
recurrent	O
disease	O
:	O
42	O
(	O
25	O
%	O
)	O
in	O
the	O
surgery	O
group	O
and	O
44	O
(	O
26	O
%	O
)	O
in	O
the	O
radiotherapy	O
group	O

Significant	O
factors	O
for	O
survival	O
in	O
univariate	O
and	O
multivariate	O
analyses	O
were	O
:	O
cervical	O
diameter	O
,	O
positive	O
lymphangiography	O
,	O
and	O
adeno-carcinomatous	O
histotype	O

48	O
(	O
28	O
%	O
)	O
surgery-group	O
patients	O
had	O
severe	O
morbidity	O
compared	O
with	O
19	O
(	O
12	O
%	O
)	O
radiotherapy-group	O
patients	O
(	O
p	O
=	O
0.0004	O
)	O

INTERPRETATION	O
:	O
There	O
is	O
no	O
treatment	O
of	O
choice	O
for	O
early-stage	O
cervical	D
carcinoma	D
in	O
terms	O
of	O
overall	O
or	O
disease-free	O
survival	O

The	O
combination	O
of	O
surgery	D
and	O
radiotherapy	D
has	O
the	O
worst	O
morbidity	O
,	O
especially	O
urological	O
complications	O

The	O
optimum	O
therapy	O
for	O
each	O
patient	O
should	O
take	O
account	O
of	O
clinical	O
factors	O
such	O
as	O
menopausal	O
status	O
,	O
age	O
,	O
medical	O
illness	O
,	O
histological	O
type	O
,	O
and	O
cervical	O
diameter	O
to	O
yield	O
the	O
best	O
cure	O
with	O
minimum	O
complications	O

Today	O
's	O
technology	O
links	O
health	O
care	O
providers	O
and	O
patients	O
across	O
town	O
,	O
in	O
the	O
next	O
state	O
or	O
even	O
another	O
country	O

Nursing	O
across	O
state	O
lines	O
poses	O
complications	O
:	O
state-bound	O
regulatory	O
and	O
licensure	O
issues	O

This	O
article	O
discusses	O
many	O
of	O
the	O
nutritional	O
topics	O
important	O
to	O
the	O
intensivist	O

Nutritional	O
assessment	O
,	O
substrate	O
immunonutrition	O
,	O
and	O
disease	O
specific	O
issues	O
are	O
presented	O

Early	O
introduction	O
of	O
enteral	O
feeds	O
and	O
the	O
use	O
of	O
nutritional	O
modulation	O
are	O
emphasized	O

PROBLEM	O
:	O
To	O
compare	O
the	O
expression	O
by	O
T-lymphocytes	O
of	O
an	O
immunomodulatory	O
protein	O
known	O
as	O
progesterone-induced	O
blocking	O
factor	O
(	O
PIBF	O
)	O
in	O
conception	O
versus	O
non-conception	O
cycles	O
even	O
when	O
there	O
has	O
been	O
definite	O
fertilization	O
and	O
embryo	O
formation	O

METHOD	O
:	O
PIBF	O
expression	O
on	O
T	O
lymphocytes	O
was	O
measured	O
using	O
an	O
immunohistochemical	O
method	O
with	O
a	O
PIBF-specific	O
polyclonal	O
antibody	O

These	O
levels	O
were	O
determined	O
in	O
patients	O
undergoing	O
three	O
types	O
of	O
therapy	O
:	O
non-in	O
vitro	O
fertilization	O
(	O
IVF	O
)	O
,	O
IVF-embryo	O
transfer	O
(	O
ET	O
)	O
,	O
and	O
frozen	O
ET	O

Sera	O
were	O
drawn	O
12	O
days	O
from	O
ovulation	O
in	O
non-IVF	O
cycles	O
or	O
9	O
days	O
after	O
ET	O
and	O
were	O
assayed	O
for	O
PIBF	O
and	O
beta	O
human	O
chorionic	O
gondotropin	O

Comparison	O
of	O
the	O
frequency	O
of	O
lymphocyte	O
expression	O
of	O
PIBF	O
in	O
pregnant	O
versus	O
non-pregnant	O
women	O
were	O
made	O

RESULTS	O
:	O
PIBF	O
was	O
detected	O
in	O
29.5	O
%	O
of	O
non-pregnant	O
women	O
and	O
52.5	O
%	O
of	O
pregnant	O
women	O

There	O
were	O
no	O
differences	O
in	O
PIBF	O
levels	O
by	O
therapy	O
used	O
in	O
non-pregnant	O
cases	O
or	O
in	O
the	O
pregnant	O
group	O

CONCLUSION	O
:	O
These	O
data	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
maternal	O
expression	O
of	O
PIBF	O
in	O
T-lymphocytes	O
soon	O
after	O
trophoblast	O
invasion	O
may	O
depend	O
on	O
successful	O
implantation	O

Many	O
amino	O
acids	O
contain	O
an	O
asymmetric	O
centre	O
,	O
occurring	O
as	O
laevorotatory	O
,	O
L	O
,	O
or	O
dextrorotatory	O
,	O
D	O
,	O
compounds	O

It	O
is	O
generally	O
assumed	O
that	O
abiotic	O
synthesis	O
of	O
amino	O
acids	O
on	O
the	O
early	O
Earth	O
resulted	O
in	O
racemic	O
mixtures	O
(	O
L-	O
and	O
D-enantiomers	O
in	O
equal	O
abundance	O
)	O

But	O
the	O
origin	O
of	O
life	O
required	O
,	O
owing	O
to	O
conformational	O
constraints	O
,	O
the	O
almost	O
exclusive	O
selection	O
of	O
either	O
L-	O
or	O
D-enantiomers	O
,	O
and	O
the	O
question	O
of	O
why	O
living	O
systems	O
on	O
the	O
Earth	O
consist	O
of	O
L-enantiomers	O
rather	O
than	O
D-enantiomers	O
is	O
unresolved	O

A	O
substantial	O
fraction	O
of	O
the	O
organic	O
compounds	O
on	O
the	O
early	O
Earth	O
may	O
have	O
been	O
derived	O
from	O
comet	O
and	O
meteorite	O
impacts	O

It	O
has	O
been	O
reported	O
previously	O
that	O
amino	O
acids	O
in	O
the	O
Murchison	O
meteorite	O
exhibit	O
an	O
excess	O
of	O
L-enantiomers	O
,	O
raising	O
the	O
possibility	O
that	O
a	O
similar	O
excess	O
was	O
present	O
in	O
the	O
initial	O
inventory	O
of	O
organic	O
compounds	O
on	O
the	O
Earth	O

The	O
stable	O
carbon	O
isotope	O
compositions	O
of	O
individual	O
amino	O
acids	O
in	O
Murchison	O
support	O
an	O
extraterrestrial	O
origin	O
--	O
rather	O
than	O
a	O
terrestrial	O
overprint	O
of	O
biological	O
amino	O
acids-although	O
reservations	O
have	O
persisted	O

Here	O
we	O
show	O
that	O
individual	O
amino-acid	O
enantiomers	O
from	O
Murchison	O
are	O
enriched	O
in	O
15N	O
relative	O
to	O
their	O
terrestrial	O
counterparts	O
,	O
so	O
confirming	O
an	O
extraterrestrial	O
source	O
for	O
an	O
L-enantiomer	O
excess	O
in	O
the	O
Solar	O
System	O
that	O
may	O
predate	O
the	O
origin	O
of	O
life	O
on	O
the	O
Earth	O

Home	O
care	O
workers	O
face	O
an	O
increasing	O
risk	O
for	O
workplace	O
violence	O

A	O
proactive	O
preventive	O
approach	O
is	O
presented	O
that	O
suggests	O
strategies	O
to	O
use	O
during	O
the	O
previsit	O
phase	O
,	O
the	O
visit	O
experience	O
,	O
and	O
on	O
an	O
ongoing	O
basis	O

The	O
miracidia	O
of	O
Fasciola	O
hepatica	O
and	O
Trichobilharzia	O
ocellata	O
approach	O
their	O
host	O
snails	O
Lymnaea	O
truncatula	O
and	O
L.	O
stagnalis	O
by	O
increasing	O
their	O
rate	O
of	O
change	O
of	O
direction	O
(	O
RCD	O
)	O
in	O
increasing	O
gradients	O
of	O
snail-conditioned	O
water	O
(	O
SCW	O
)	O
,	O
and	O
they	O
perform	O
a	O
turnback	O
swimming	O
in	O
decreasing	O
gradients	O

Both	O
hostfinding	O
responses	O
in	O
both	O
species	O
were	O
induced	O
by	O
glycoconjugates	O
with	O
a	O
molecular	O
weight	O
of	O
>	O
30	O
kDa	O
that	O
were	O
sensitive	O
to	O
hydrolysis	O
with	O
pronase	O
E	O
and	O
oxidation	O
with	O
NaIO4	O

Alkaline	O
cleavage	O
revealed	O
that	O
they	O
contained	O
carbohydrates	O
linked	O
O-glycosidically	O
via	O
serine	O
and	O
N-acetylgalactosamine	O

Miracidia	O
clearly	O
preferred	O
SCW	O
from	O
their	O
specific	O
host	O
snail	O
versus	O
other	O
sympatric	O
snail	O
species	O
and	O
did	O
not	O
respond	O
to	O
water	O
conditioned	O
with	O
fish	O
,	O
tadpoles	O
,	O
or	O
leeches	O

Differences	O
in	O
the	O
chemical	O
characteristics	O
of	O
SCW	O
from	O
the	O
intermediate	O
hosts	O
L.	O
truncatula	O
and	O
L.	O
stagnalis	O
could	O
be	O
shown	O
by	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
,	O
blotting	O
,	O
and	O
subsequent	O
carbohydrate	O
detection	O

The	O
first	O
step	O
of	O
purification	O
of	O
the	O
effective	O
signaling	O
SCW	O
components	O
from	O
both	O
snail	O
species	O
was	O
achieved	O
by	O
ion-exchange	O
chromatography	O

Black	O
patients	O
with	O
colon	D
cancer	D
in	O
the	O
Black/White	O
Cancer	O
Survival	O
Study	O
were	O
found	O
to	O
have	O
a	O
poorer	O
survival	O
than	O
white	O
patients	O

More	O
advanced-stage	O
disease	O
at	O
diagnosis	O
was	O
the	O
primary	O
determinant	O
,	O
accounting	O
for	O
60	O
%	O
of	O
the	O
excess	O
mortality	O

After	O
adjusting	O
for	O
stage	O
,	O
factors	O
such	O
as	O
poverty	O
,	O
other	O
socioeconomic	O
conditions	O
,	O
and	O
treatment	O
did	O
not	O
further	O
explain	O
the	O
remaining	O
survival	O
deficit	O

This	O
study	O
examined	O
the	O
aggressiveness	O
of	O
colon	D
tumors	D
in	O
blacks	O
and	O
whites	O
to	O
explore	O
its	O
role	O
in	O
the	O
racial	O
survival	O
differences	O

Tumor	O
characteristics	O
of	O
703	O
cases	O
of	O
newly	O
diagnosed	O
invasive	O
colon	O
adenocarcinoma	D
were	O
centrally	O
evaluated	O
by	O
a	O
gastrointestinal	O
pathologist	O
,	O
blinded	O
in	O
regard	O
to	O
the	O
age	O
,	O
race	O
,	O
and	O
sex	O
of	O
the	O
patients	O

Blacks	O
were	O
less	O
likely	O
to	O
have	O
poorly	O
differentiated	O
(	O
grade	O
3	O
)	O
tumors	D
(	O
odds	O
ratio	O
(	O
OR	O
)	O
,	O
0.44	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.22-0.88	O
)	O
and	O
lymphoid	O
reaction	O
(	O
OR	O
,	O
0.49	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.26-0.90	O
)	O
when	O
compared	O
with	O
whites	O

These	O
black/white	O
(	O
B/W	O
)	O
differences	O
remained	O
statistically	O
significant	O
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
metropolitan	O
area	O
,	O
summary	O
stage	O
,	O
socioeconomic	O
status	O
,	O
body	O
mass	O
index	O
,	O
and	O
health	O
care	O
access	O
and	O
utilization	O

In	O
addition	O
,	O
blacks	O
were	O
less	O
likely	O
to	O
have	O
high-grade	O
(	O
grade	O
3	O
)	O
nuclear	D
atypia	D
,	O
mitotic	O
activity	O
,	O
and	O
tubule	O
formation	O
,	O
although	O
these	O
ORs	O
did	O
not	O
reach	O
a	O
statistical	O
significance	O
level	O
of	O
0.05	O

Similar	O
B/W	O
differences	O
were	O
observed	O
for	O
patients	O
with	O
advanced	O
disease	O
but	O
not	O
with	O
early	O
stage	O

Comparison	O
by	O
anatomical	O
subsite	O
showed	O
that	O
blacks	O
had	O
statistically	O
significantly	O
better	O
differentiated	O
tumors	D
for	O
cancers	D
of	O
the	O
proximal	O
and	O
transverse	O
colon	O
but	O
not	O
for	O
the	O
distal	O

No	O
racial	O
differences	O
were	O
found	O
for	O
blood	O
vessel	O
and	O
lymphatic	D
invasion	D
,	O
necrosis	D
,	O
fibrosis	D
,	O
and	O
mucinous	O
type	O
of	O
histology	O

The	O
findings	O
,	O
therefore	O
,	O
are	O
the	O
opposite	O
of	O
those	O
hypothesized	O

After	O
adjusting	O
for	O
stage	O
,	O
more	O
aggressive	O
tumor	O
characteristics	O
do	O
not	O
explain	O
the	O
adverse	O
survival	O
differential	O
in	O
blacks	O

This	O
suggests	O
that	O
there	O
may	O
be	O
racial	O
differences	O
in	O
environmental	O
exposure	O
,	O
and	O
that	O
the	O
intensity	O
and	O
mode	O
of	O
delivery	O
of	O
carcinogen	O
insult	O
as	O
well	O
as	O
host	O
susceptibility	O
may	O
differ	O
by	O
race	O
and	O
anatomical	O
subsite	O

Future	O
studies	O
should	O
explore	O
the	O
B/W	O
differences	O
in	O
tumor	O
biology	O
using	O
molecular	O
markers	O
that	O
precede	O
the	O
conventional	O
histological	O
parameters	O
evaluated	O
here	O

A	O
new	O
method	O
is	O
described	O
for	O
detection	O
of	O
mutations	O
in	O
the	O
lysosomal	O
alpha-glucosidase	O
gene	O
(	O
GAA	O
)	O
leading	O
to	O
Glycogen	D
Storage	D
Disease	D
type	D
II	D
(	D
GSDII	D
)	D

A	O
key	O
feature	O
of	O
the	O
method	O
is	O
isolation	O
and	O
reverse	O
transcription	O
of	O
mRNA	O
followed	O
by	O
PCR	O
amplification	O
of	O
lysosomal	O
alpha-glucosidase	O
cDNA	O
with	O
M13-extended	O
primers	O

Dye	O
labeled	O
primers	O
are	O
used	O
for	O
cycle	O
sequencing	O
and	O
an	O
ABI	O
PRISM	O
377	O
DNA	O
sequencing	O
system	O
for	O
analysis	O

The	O
method	O
is	O
rapid	O
and	O
complementary	O
to	O
the	O
automated	O
sequencing	O
of	O
all	O
the	O
19	O
,	O
PCR	O
amplified	O
,	O
coding	O
exons	O
of	O
the	O
GAA	O
gene	O

The	O
advantages	O
and	O
pitfalls	O
of	O
this	O
new	O
method	O
are	O
discussed	O
in	O
the	O
light	O
of	O
the	O
results	O
obtained	O
with	O
an	O
infantile	O
GSDII	O
patient	O

A	O
new	O
splice	O
site	O
mutation	O
in	O
the	O
GAA	O
gene	O
of	O
this	O
patient	O
was	O
identified	O
,	O
IVS16	O
(	O
+2T	O
--	O
>	O
C	O
)	O
,	O
resulting	O
in	O
the	O
deletion	O
of	O
16	O
base	O
pairs	O
of	O
exon	O
16	O

The	O
presence	O
of	O
clinical	O
autonomic	D
dysfunction	D
in	O
patients	O
with	O
neurologic	D
diseases	D
,	O
such	O
as	O
multiple	D
sclerosis	D
,	O
Parkinson	D
's	D
disease	D
,	O
and	O
cerebrovascular	O
accident	O
,	O
has	O
become	O
increasingly	O
recognized	O
in	O
the	O
past	O
decade	O

Very	O
few	O
autonomic	O
tests	O
have	O
been	O
done	O
on	O
pediatric	O
patients	O
thus	O
far	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
autonomic	O
function	O
in	O
patients	O
with	O
cerebral	D
palsy	D
using	O
two	O
noninvasive	O
tests	O
:	O
sympathetic	O
skin	O
response	O
(	O
SSR	O
)	O
and	O
R-R	O
interval	O
variation	O
(	O
RRIV	O
)	O

Twenty-four	O
patients	O
with	O
cerebral	D
palsy	D
and	O
24	O
control	O
subjects	O
between	O
the	O
ages	O
of	O
4	O
and	O
12	O
yr	O
were	O
enrolled	O
in	O
this	O
study	O

There	O
was	O
no	O
significant	O
difference	O
of	O
mean	O
latency	O
,	O
amplitude	O
,	O
or	O
amplitude	O
ratio	O
of	O
SSR	O
between	O
the	O
two	O
groups	O
under	O
electric	O
stimulus	O
,	O
startling	O
stimulus	O
,	O
and	O
deep	O
breathing	O
conditions	O

No	O
significant	O
difference	O
in	O
frequency	O
of	O
absent	O
response	O
and	O
asymmetric	O
response	O
was	O
also	O
noted	O

Mean	O
heart	O
rate	O
under	O
relaxed	O
sitting	O
condition	O
was	O
significantly	O
higher	O
in	O
the	O
study	O
group	O

Significant	O
negative	O
correlation	O
between	O
heart	O
rate	O
and	O
age	O
was	O
noted	O
in	O
the	O
control	O
group	O
but	O
was	O
not	O
present	O
in	O
the	O
study	O
group	O

Also	O
,	O
there	O
was	O
no	O
statistical	O
difference	O
of	O
mean	O
RRIV	O
between	O
the	O
two	O
groups	O

No	O
objective	O
evidence	O
of	O
autonomic	O
disturbance	O
in	O
patients	O
with	O
cerebral	D
palsy	D
was	O
found	O
in	O
this	O
study	O

A	O
two-credits	O
per	O
semester	O
clinical	O
medicine	O
course	O
was	O
established	O
in	O
the	O
Department	O
of	O
Physical	O
Medicine	O
and	O
Rehabilitation	O
(	O
PM	O
&	O
#	O
38	O
;	O
R	O
)	O
in	O
cooperation	O
with	O
the	O
Johns	O
Hopkins	O
University	O
undergraduate	O
Human	O
Biology	O
faculty	O
to	O
present	O
the	O
variety	O
of	O
inpatient	O
consultation	O
personnel	O
,	O
units	O
,	O
patient	O
diagnostic	O
groups	O
,	O
and	O
functional	O
problems	O

College	O
students	O
spend	O
4	O
hr	O
weekly	O
on	O
the	O
PM	O
&	O
#	O
38	O
;	O
R	O
consultation	O
service	O
as	O
team	O
members	O
under	O
resident	O
supervision	O

The	O
curriculum	O
emphasizes	O
student	O
understanding	O
of	O
the	O
roles	O
of	O
rehabilitation	O
team	O
members	O

Objectives	O
include	O
demonstration	O
of	O
working	O
knowledge	O
of	O
the	O
Biopsychosocial	O
Model	O
,	O
the	O
World	O
Health	O
Organization	O
Model	O
of	O
disablement	O
and	O
interdisciplinary	O
rehabilitation	O
intervention	O

The	O
course	O
includes	O
simulations	O
of	O
physical	O
impairments	O
,	O
demonstrations	O
of	O
adaptive	O
equipment	O
,	O
interactive	O
chart	O
reviews	O
,	O
readings	O
,	O
and	O
audio	O
lectures	O

A	O
retrospective	O
sequential	O
review	O
was	O
made	O
of	O
the	O
last	O
100	O
physical	O
medicine	O
and	O
rehabilitation	O
consultations	O
with	O
student	O
attendance	O

The	O
results	O
confirm	O
student	O
exposure	O
to	O
many	O
ward	O
settings	O
(	O
surgery	O
,	O
30	O
%	O
;	O
neurology/neurosurgery	O
,	O
28	O
%	O
;	O
medicine	O
,	O
24	O
%	O
;	O
intensive	O
care	O
,	O
15	O
%	O
;	O
oncology	O
,	O
2	O
%	O
;	O
and	O
psychiatry	O
,	O
1	O
%	O
)	O
,	O
patient	O
complexity	O
(	O
averaging	O
10	O
problems	O
)	O
,	O
and	O
multiple	O
ICD-9	O
diagnosis	O
categories	O
(	O
circulatory	O
,	O
36	O
%	O
;	O
neurologic	O
,	O
22	O
%	O
;	O
musculoskeletal	O
,	O
17	O
%	O
;	O
neoplasms	O
,	O
10	O
%	O
;	O
injury	O
,	O
5	O
%	O
;	O
endocrine	O
,	O
4	O
%	O
;	O
infections	O
,	O
3	O
%	O
;	O
and	O
others	O
,	O
3	O
%	O
)	O

The	O
rehabilitation	O
consultation	O
service	O
is	O
particularly	O
effective	O
as	O
an	O
introduction	O
to	O
hospital-based	O
medical	O
practice	O
due	O
to	O
the	O
diagnostic	O
variety	O
of	O
the	O
patients	O
,	O
the	O
functional	O
approach	O
of	O
rehabilitation	O
,	O
and	O
student	O
exposure	O
to	O
multiple	O
hospital	O
settings	O

The	O
Biopsychosocial	O
Model	O
of	O
medical	O
practice	O
is	O
demonstrated	O
through	O
multiple	O
interdisciplinary	O
perspectives	O
of	O
needs	O
and	O
interventions	O
for	O
patients	O
with	O
obvious	O
functional	O
deficits	O

This	O
process	O
develops	O
a	O
rudimentary	O
understanding	O
of	O
the	O
effect	O
of	O
illness	O
on	O
the	O
person	O
and	O
the	O
variety	O
of	O
medically	O
effective	O
therapeutic	O
modalities	O

This	O
study	O
is	O
designed	O
to	O
investigate	O
the	O
immediate	O
effectiveness	O
of	O
electrotherapy	T
on	O
myofascial	D
trigger	D
points	D
of	D
upper	D
trapezius	D
muscle	D

Sixty	O
patients	O
(	O
25	O
males	O
and	O
35	O
females	O
)	O
who	O
had	O
myofascial	D
trigger	D
points	D
in	O
one	O
side	O
of	O
the	O
upper	O
trapezius	O
muscles	O
were	O
studied	O

The	O
involved	O
upper	O
trapezius	O
muscles	O
were	O
treated	O
with	O
three	O
different	O
methods	O
according	O
to	O
a	O
random	O
assignment	O
:	O
group	O
A	O
muscles	O
(	O
n	O
=	O
18	O
)	O
were	O
given	O
placebo	O
treatment	O
(	O
control	O
group	O
)	O
;	O
group	O
B	O
muscles	O
(	O
n	O
=	O
20	O
)	O
were	O
treated	O
with	O
electrical	T
nerve	T
stimulation	T
(	T
ENS	T
)	T
therapy	T
;	O
and	O
group	O
C	O
muscles	O
(	O
n	O
=	O
22	O
)	O
were	O
given	O
electrical	T
muscle	T
stimulation	T
(	T
EMS	T
)	T
therapy	T

The	O
effectiveness	O
of	O
treatment	O
was	O
assessed	O
by	O
conducting	O
three	O
measurements	O
on	O
each	O
muscle	O
before	O
and	O
immediately	O
after	O
treatment	O
:	O
subjective	O
pain	O
intensity	O
(	O
(	O
PI	O
)	O
with	O
a	O
visual	O
analog	O
scale	O
)	O
,	O
pressure	O
pain	O
threshold	O
(	O
(	O
PT	O
)	O
with	O
algometry	O
)	O
,	O
and	O
range	O
of	O
motion	O
(	O
(	O
ROM	O
)	O
with	O
a	O
goniometer	O
)	O
of	O
upper	O
trapezius	O
muscle	O
(	O
lateral	O
bending	O
of	O
cervical	O
spine	O
to	O
the	O
opposite	O
side	O
)	O

When	O
the	O
effectiveness	O
of	O
treatment	O
was	O
compared	O
with	O
that	O
of	O
the	O
placebo	O
group	O
(	O
group	O
A	O
)	O
,	O
there	O
was	O
significant	O
improvement	O
in	O
PI	O
and	O
PT	O
in	O
group	O
B	O
(	O
P	O
&	O
#	O
60	O
;	O
0.01	O
)	O
but	O
not	O
in	O
group	O
C	O
(	O
P	O
>	O
0.05	O
)	O

The	O
improvement	O
of	O
ROM	O
was	O
significantly	O
more	O
in	O
group	O
C	O
(	O
P	O
&	O
#	O
60	O
;	O
0.01	O
)	O
as	O
compared	O
with	O
that	O
in	O
group	O
A	O
or	O
group	O
B	O

When	O
each	O
group	O
was	O
divided	O
into	O
two	O
additional	O
subgroups	O
based	O
on	O
the	O
initial	O
PI	O
,	O
it	O
was	O
found	O
that	O
ENS	O
could	O
reduce	O
PI	O
and	O
increase	O
PT	O
significantly	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
,	O
but	O
did	O
not	O
significantly	O
(	O
P	O
>	O
0.05	O
)	O
improve	O
ROM	O
,	O
as	O
compared	O
with	O
the	O
placebo	O
group	O
for	O
both	O
subgroups	O

EMS	O
could	O
significantly	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
improve	O
ROM	O
,	O
but	O
not	O
PT	O
,	O
better	O
than	O
the	O
placebo	O
groups	O
,	O
for	O
either	O
subgroup	O
